Form N-CSR DEUTSCHE DWS SECURITIES For: May 31

Article Stock Quotes (2)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 4/23/2024

1. TSLA
2. SPY
3. GM
4. SPOT
5. AMZN

6. SHW
7. AAPL
8. MINN
9. NVDA
10. IBM

Top News Most Read Special Reports

August 3, 2018 2:56 PM EDT

E-mail

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D. C. 20549

FORM N-CSR

Investment Company Act file number: 811-02021

Deutsche DWS Securities Trust

(Exact Name of Registrant as Specified in Charter)

345 Park Avenue

New York, NY 10154-0004

(Address of Principal Executive Offices) (Zip Code)

Registrant’s Telephone Number, including Area Code: (212) 250-2500

Diane Kenneally

1 International Place

Boston, MA 02110

(Name and Address of Agent for Service)

Date of fiscal year end:	5/31

Date of reporting period:	5/31/2018

ITEM 1.

REPORT TO STOCKHOLDERS

LOGO

May 31, 2018

Annual Report

to Shareholders

DWS Health and Wellness Fund

(formerly Deutsche Health and Wellness Fund)

LOGO

Contents


	3			Letter to Shareholders
	4			Portfolio Management Review
	7			Performance Summary
	9			Portfolio Summary
	10			Investment Portfolio
	15			Statement of Assets and Liabilities
	17			Statement of Operations
	18			Statements of Changes in Net Assets
	19			Financial Highlights


	23			Notes to Financial Statements
	33			Report of Independent Registered Public Accounting Firm
	35			Information About Your Fund’s Expenses
	36			Tax Information
	37			Advisory Agreement Board Considerations and Fee Evaluation
	42			Board Members and Officers
	47			Account Management Resources

This report must be preceded or accompanied by a prospectus. To obtain a summary prospectus, if available, or prospectus for any of our funds, refer to the Account Management Resources information provided in the back of this booklet. We advise you to consider the Fund’s objectives, risks, charges and expenses carefully before investing. The summary prospectus and prospectus contain this and other important information about the Fund. Please read the prospectus carefully before you invest.

Any fund that concentrates in a particular segment of the market will generally be more volatile than a fund that invests more broadly. The Fund may lend securities to approved institutions. Stocks may decline in value. Please read the prospectus for details.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services.

NOT FDIC/NCUA INSURED NO BANK GUARANTEE MAY LOSE VALUE NOT A DEPOSIT NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY


2		\|		DWS Health and Wellness Fund

Letter to Shareholders

Dear Shareholder:

As you know, we as Deutsche Asset Management adopted our existing European brand, DWS, globally, earlier this year. In connection with that change, “DWS” will now replace “Deutsche” in most of our open-end mutual fund names, including share classes for certain money market funds which previously included the “Deutsche” in their names.

Building on more than 60 years of experience and a reputation for excellence in Germany and across Europe, DWS is known for the values that we see as core elements to our investors’ success: Excellence, Entrepreneurship, Sustainability and Integrity. We aim to demonstrate these qualities in all that we do.

Please remember that, as part of this name change, our website also has a new address: DWS.com. For your convenience, the deutschefunds.com address will remain live and automatically redirect you to our new site. As always, we invite you to visit us online frequently to access the most current insights from our CIO, economists and investment specialists.

Thank you for your ongoing trust in us. We look forward to bringing you the very best in investment insight, strategies and solutions for many years to come.

Best regards,

LOGO

Hepsen Uzcan

President, DWS Funds

Assumptions, estimates and opinions contained in this document constitute our judgment as of the date of the document and are subject to change without notice. Any projections are based on a number of assumptions as to market conditions and there can be no guarantee that any projected results will be achieved. Past performance is not a guarantee of future results.


		DWS Health and Wellness Fund		\|			3


Portfolio Management Review		(Unaudited)

Overview of Market and Fund Performance

All performance information below is historical and does not guarantee future results. Returns shown are for Class A shares, unadjusted for sales charges. Investment return and principal fluctuate, so your shares may be worth more or less when redeemed. Current performance may differ from performance data shown. Please visit dws.com for the most recent month-end performance of all share classes. Fund performance includes reinvestment of all distributions. Unadjusted returns do not reflect sales charges and would have been lower if they had. Please refer to pages 7 through 8 for more complete performance information.

Investment Strategy

In seeking long-term growth of capital, the Fund’s managers employ bottom-up research and top-down analysis which considers economic outlook and an industry’s potential to benefit from changes in the overall business environment, and a growth orientation in making the Fund’s health care and wellness sector investments.

Over the past 12 months, health care stocks underperformed the broader equity market, driven by a joint announcement from Amazon.com,* Berkshire Hathaway* and JP Morgan Chase* that they were forming an independent health care company, which raised concerns among investors regarding the potential competitive threat to pricing within the U.S. health care system from the collaboration. In addition, drug pricing continues to be an area of focus for regulators and the U.S. administration.

For its most recent fiscal year ended May 31, 2018, the Fund posted a 9.01% total return, underperforming the 14.38% return of the S&P 500 Index, but outperforming the 6.31% return of the MSCI World Health Care Index.

Positive Contributors to Fund Performance

An overweight within small- and mid-cap biotechnology stocks contributed meaningfully to performance during the 12-month period. The largest contribution to returns came from the Fund’s position in Bluebird Bio, Inc., as the company reported positive clinical data for its cellular therapy to treat multiple myeloma, a cancer of the white blood cells. In addition, the company continues to make progress on its gene therapies for blood-based disorders. Other major contributors within biotechnology included Sarepta Therapeutics, Inc., driven by the strong launch of the


4		\|		DWS Health and Wellness Fund

company’s drug for Duchenne muscular dystrophy, an inherited disorder that leads to progressive muscle weakness; Loxo Oncology, Inc., which reported positive clinical data for genetically-defined cancers; and Neurocrine Biosciences, Inc., which had a strong launch of its drug for tardive dyskinesia, a disorder that causes involuntary body movements. Lastly, underweights in Roche Holding AG and Johnson & Johnson added to performance. Shares of Roche underperformed as investors remained concerned about declining sales from patent expirations for several key products, while Johnson & Johnson shares declined as investor appetite for bond proxies diminished.

“We

believe that over the long term, health care stocks can potentially outperform the broader stock market as represented by the S&P 500 Index, as their growth profile and medical innovations have continued to capture investor interest.”

Negative Contributors to Fund Performance

The largest detractors from performance derived from overweight positions in two biotechnology companies: TESARO, Inc. and Incyte Corp. After very strong performance from mid-2016 to early 2017 due to Food and Drug Administration approval of its cancer drug as well as takeover speculation, TESARO shares weakened significantly as the drug launch did not meet investor expectations, new competitors emerged and the potential acquisition did not materialize. Shares of Incyte Corp. declined due to negative clinical data for their key drug in development for melanoma, a serious cancer of the skin. In addition, an underweight in AbbVie, Inc. was subtractive, as investors rewarded the durability of AbbVie’s sales for its key drug Humira to treat rheumatoid arthritis. Lastly, holdings in two specialty pharmaceutical companies, Allergan PLC and Alkermes PLC, weighed on performance: Investors grew concerned about competitive threats to Allergan’s two key drugs, and Alkermes reported mixed clinical data for its drug to treat depression.

Outlook

We believe that in the long term, health care stocks can potentially outperform the broader stock market as represented by the S&P 500 Index, , as their growth profile and medical innovations have continued to capture investor interest. We also believe that the prospects for health care stocks are promising, based on positive global demographic trends and the continuing emergence of new technologies.

*	Not held in the portfolio as of May 31, 2018.


		DWS Health and Wellness Fund		\|			5

Portfolio Management Team

Leefin Lai, CFA, CPA, Managing Director.

Lead Portfolio Manager of the Fund. Began managing the Fund in 2001.

–	Joined DWS in 2001.

–	Previously served as an analyst for Salomon Smith Barney and PaineWebber and as Vice President/Analyst for Citigroup Global Asset Management and Scudder Kemper Investments.

–	Investment industry experience began in 1991.

–	BS and MBA, University of Illinois.

Peter Barsa, Director.

Portfolio Manager of the Fund. Began managing the Fund in 2014.

–	Joined DWS in 1999.

–	Portfolio Manager and Equity Research Analyst for Small and Mid Cap Equities: New York.

–	Equity research analyst covering consumer discretionary and consumer staples and global small cap equity research generalist.

–	BS in Finance, Villanova University.

Michael A. Sesser, CFA, Director.

Portfolio Manager of the Fund. Began managing the Fund in 2014.

–	Joined DWS in 2009.

–	Portfolio Manager and Equity Research Analyst: New York.

–	Previously, Business Intelligence Analyst, Corporate Executive Board (now owned by Gartner) from 2005-2007; Research Associate, Compass Lexecon (now owned by FTI Consulting) from 2003-2005.

–	BA in Ethics, Politics & Economics, Yale University; MBA (with distinction), Stephen M. Ross School of Business, University of Michigan.

The views expressed reflect those of the portfolio management team only through the end of the period of the report as stated on the cover. The management team’s views are subject to change at any time based on market and other conditions and should not be construed as a recommendation. Past performance is no guarantee of future results. Current and future portfolio holdings are subject to risk.

Terms to Know

The Standard & Poor’s 500 (S&P 500) Index is an unmanaged, capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries.

The MSCI World Health Care Index is designed to capture the large and mid cap segments across 23 Developed Markets (DM) countries. All securities in the index are classified in the Health Care sector as per the Global Industry Classification Standard (GICS^®).

Index returns do not reflect fees or expenses and it is not possible to invest directly into an index.

Overweight means that the Fund holds a higher weighting in a given sector or security than the benchmark. Underweight means the Fund holds a lower weighting.


6		\|		DWS Health and Wellness Fund


Performance Summary		May 31, 2018 (Unaudited)


Class A	1-Year		5-Year		10-Year
Average Annual Total Returns as of 5/31/18
Unadjusted for Sales Charge		9.01%		12.19%		11.02%
Adjusted for the Maximum Sales Charge (max 5.75% load)		2.74%		10.87%		10.37%
S&P 500^® Index^†		14.38%		12.98%		9.14%
MSCI World Health Care Index^††		6.31%		10.08%		9.70%

Class C	1-Year		5-Year		10-Year
Average Annual Total Returns as of 5/31/18
Unadjusted for Sales Charge		8.26%		11.37%		10.21%
Adjusted for the Maximum Sales Charge (max 1.00% CDSC)		8.26%		11.37%		10.21%
S&P 500^® Index^†		14.38%		12.98%		9.14%
MSCI World Health Care Index^††		6.31%		10.08%		9.70%

Class S	1-Year		5-Year		10-Year
Average Annual Total Returns as of 5/31/18
No Sales Charges		9.32%		12.48%		11.32%
S&P 500^® Index^†		14.38%		12.98%		9.14%
MSCI World Health Care Index^††		6.31%		10.08%		9.70%

Institutional Class	1-Year		5-Year		10-Year
Average Annual Total Returns as of 5/31/18
No Sales Charges		9.30%		12.47%		11.41%
S&P 500^® Index^†		14.38%		12.98%		9.14%
MSCI World Health Care Index^††		6.31%		10.08%		9.70%

Performance in the Average Annual Total Returns table(s) above and the Growth of an Assumed $10,000 Investment line graph that follows is historical and does not guarantee future results. Investment return and principal fluctuate, so your shares may be worth more or less when redeemed. Current performance may differ from performance data shown. Please visit dws.com for the Fund’s most recent month-end performance. Fund performance includes reinvestment of all distributions. Unadjusted returns do not reflect sales charges and would have been lower if they had.

The gross expense ratios of the Fund, as stated in the fee table of the prospectus dated October 1, 2017 are 1.37%, 2.12%, 1.08% and 1.07% for Class A, Class C, Class S and Institutional Class shares, respectively, and may differ from the expense ratios disclosed in the Financial Highlights tables in this report.

Index returns do not reflect any fees or expenses and it is not possible to invest directly into an index.


		DWS Health and Wellness Fund		\|			7

Generally accepted accounting principles require adjustments to be made to the net assets of the Fund at period end for financial reporting purposes only, and as such, the total return based on the unadjusted net asset value per share may differ from the total return reported in the financial highlights.

Growth of an Assumed $10,000 Investment
(Adjusted for Maximum Sales Charge)

LOGO

The Fund’s growth of an assumed $10,000 investment is adjusted for the maximum sales charge of 5.75%. This results in a net initial investment of $9,425.

The growth of $10,000 is cumulative.

Performance of other share classes will vary based on the sales charges and the fee structure of those classes.

^†	The Standard & Poor’s 500 (S&P 500) Index is an unmanaged, capitalization-weighted index of 500 stocks. The index is designed to measure performance of the broad domestic economy through changes in the aggregate market value of 500 stocks representing all major industries.

^††	The MSCI World Health Care Index is designed to capture the large and mid cap segments across 23 Developed Markets (DM) countries. All securities in the index are classified in the Health Care sector as per the Global Industry Classification Standard (GICS^®).


	Class A		Class C		Class S		Institutional Class
Net Asset Value
5/31/18	$	35.96	$	28.19	$	38.53	$	40.10
5/31/17	$	35.19	$	28.25	$	37.53	$	38.97
Distribution Information as of 05/31/18
Income Dividends, Twelve Months		—		—	$	.09	$	.10
Capital Gain Distributions, Twelve Months	$	2.36	$	2.36	$	2.36	$	2.36


8		\|		DWS Health and Wellness Fund


Portfolio Summary		(Unaudited)

Asset Allocation (As a % of Investment Portfolio excluding Securities Lending Collateral)	5/31/18		5/31/17
Common Stocks		97%		97%
Cash Equivalents		3%		3%
		100%		100%

Sector Diversification (As a % of Investment Portfolio excluding Cash Equivalents and Securities Lending Collateral)	5/31/18		5/31/17
Pharmaceuticals
Major Pharmaceuticals		25%		26%
Specialty Pharmaceuticals		6%		7%
Medical Supply & Specialty		24%		22%
Biotechnology		23%		23%
Health Care Services		22%		22%
		100%		100%


Ten Largest Equity Holdings at May 31, 2018 (29.3% of Net Assets)
	1.	UnitedHealth Group, Inc.	6.3%
		Operator of organized health systems
	2.	Johnson & Johnson	3.7%
		Provider of health care products
	3.	Medtronic PLC	2.9%
		Develops therapeutic and diagnostic medical products
	4.	Pfizer, Inc.	2.9%
		Manufacturer of prescription pharmaceuticals and nonprescription self-medications
	5.	Abbott Laboratories	2.4%
		Developer of health care products
	6.	Merck & Co., Inc.	2.4%
		Global pharmaceutical company
	7.	Bristol-Myers Squibb Co.	2.3%
		Producer of diversified pharmaceuticals and other products
	8.	Biogen, Inc.	2.2%
		Developer, marketer and manufacturer of neurological therapies
	9.	Boston Scientific Corp.	2.1%
		Developer and producer of medical devices
	10.	Stryker Corp.	2.1%
		Provider of healthcare equipment and supplies

Portfolio holdings and characteristics are subject to change.

For more complete details about the Fund’s investment portfolio, see page 10. A quarterly Fact Sheet is available on dws.com or upon request. Please see the Account Management Resources section on page 47 for contact information.


		DWS Health and Wellness Fund		\|			9


Investment Portfolio		as of May 31, 2018


	Shares		Value ($)
Common Stocks 96.8%
Health Care 96.8%
Biotechnology 21.4%
Agios Pharmaceuticals, Inc.*		5,200		486,200
Alexion Pharmaceuticals, Inc.*		33,701		3,913,697
Alkermes PLC*		32,429		1,530,649
Alnylam Pharmaceuticals, Inc.*		7,099		706,138
Amgen, Inc.		30,946		5,558,521
Amicus Therapeutics, Inc.*		72,503		1,225,301
Arena Pharmaceuticals, Inc.*		35,620		1,628,546
Argenx SE (ADR)*		5,323		508,346
Array BioPharma, Inc.*		51,129		835,959
Biogen, Inc.*		21,578		6,343,069
BioMarin Pharmaceutical, Inc.*		32,231		2,911,749
Bluebird Bio, Inc.*		7,346		1,315,301
Blueprint Medicines Corp.*		6,254		525,836
Celgene Corp.*		40,261		3,167,735
Clovis Oncology, Inc.*		16,494		774,558
CRISPR Therapeutics AG* (a)		4,925		339,382
Cymabay Therapeutics, Inc.*		20,788		269,620
Cytokinetics, Inc.*		20,041		180,369
DBV Technologies SA (ADR)* (a)		17,990		404,775
Exelixis, Inc.*		33,251		689,293
Galapagos NV (ADR)*		8,878		904,047
Gilead Sciences, Inc.		64,160		4,324,384
Global Blood Therapeutics, Inc.*		7,458		359,103
Heron Therapeutics, Inc.*		28,818		939,467
Incyte Corp.*		20,377		1,391,138
Ligand Pharmaceuticals, Inc.*		8,706		1,673,554
Loxo Oncology, Inc.*		8,665		1,536,564
Medicines Co.*		26,781		906,805
Neurocrine Biosciences, Inc.*		16,573		1,595,317
Regeneron Pharmaceuticals, Inc.*		4,807		1,443,638
REGENXBIO, Inc.*		17,894		969,855
Sage Therapeutics, Inc.*		7,858		1,199,838
Sarepta Therapeutics, Inc.*		10,476		983,173
Seattle Genetics, Inc.*		26,201		1,584,898
TESARO, Inc.*		17,722		811,136
Ultragenyx Pharmaceutical, Inc.*		10,900		797,880
Vertex Pharmaceuticals, Inc.*		36,745		5,658,730
Zogenix, Inc.*		13,540		576,127

				60,970,698

The accompanying notes are an integral part of the financial statements.


10		\|		DWS Health and Wellness Fund


	Shares		Value ($)
Health Care Services 20.8%
Aetna, Inc.		21,054		3,708,241
Amedisys, Inc.*		12,710		970,408
AMN Healthcare Services, Inc.*		17,026		961,969
Anthem, Inc.		22,468		4,974,865
athenahealth, Inc.*		10,081		1,516,888
Centene Corp.*		28,769		3,370,576
Cerner Corp.*		10,944		653,138
Cigna Corp.		16,295		2,759,884
Envision Healthcare Corp.*		29,045		1,245,450
Express Scripts Holding Co.*		11,752		890,919
HCA Healthcare, Inc.		17,516		1,806,600
Humana, Inc.		19,106		5,559,464
McKesson Corp.		9,349		1,326,997
Quest Diagnostics, Inc.		34,390		3,663,567
Thermo Fisher Scientific, Inc.		24,624		5,128,440
UnitedHealth Group, Inc.		74,153		17,908,691
Universal Health Services, Inc. “B”		8,435		969,856
WellCare Health Plans, Inc.*		7,655		1,696,884

				59,112,837
Medical Supply & Specialty 23.8%
Abbott Laboratories		112,903		6,946,922
Agilent Technologies, Inc.		25,436		1,574,997
Align Technology, Inc.*		2,657		881,991
Baxter International, Inc.		57,406		4,066,641
Becton, Dickinson & Co.		22,606		5,009,264
Boston Scientific Corp.*		200,213		6,084,473
Cardiovascular Systems, Inc.*		57,162		1,720,576
Danaher Corp.		42,895		4,258,616
DENTSPLY SIRONA, Inc.		29,346		1,285,648
DexCom, Inc.*		5,600		492,744
Edwards Lifesciences Corp.*		19,330		2,654,202
Exact Sciences Corp.*		17,039		1,014,502
IDEXX Laboratories, Inc.*		4,194		873,233
Illumina, Inc.*		7,927		2,159,632
Integra LifeSciences Holdings Corp.*		19,675		1,269,824
Intuitive Surgical, Inc.*		10,897		5,009,024
Koninklijke Philips NV		36,722		1,507,635
Masimo Corp.*		13,562		1,343,316
Medtronic PLC		95,055		8,205,148
Stryker Corp.		33,892		5,897,886
Teleflex, Inc.		6,957		1,858,632
Wright Medical Group NV* (a)		62,901		1,570,009
Zimmer Biomet Holdings, Inc.		18,293		2,039,852

				67,724,767

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			11


	Shares			Value ($)
Pharmaceuticals 30.8%
AbbVie, Inc.		50,595			5,005,869
Allergan PLC		27,024			4,075,219
AmerisourceBergen Corp.		9,929			815,568
AstraZeneca PLC (ADR)		155,092			5,743,057
Avadel Pharmaceuticals PLC (ADR)* (a)		18,700			130,526
Bayer AG (Registered)		35,097			4,202,963
Bristol-Myers Squibb Co.		122,625			6,452,527
Eli Lilly & Co.		67,442			5,735,268
GlaxoSmithKline PLC (ADR)		72,464			2,936,241
Jazz Pharmaceuticals PLC*		11,966			2,022,254
Johnson & Johnson		88,531			10,590,078
Merck & Co., Inc.		114,074			6,790,825
Mirati Therapeutics, Inc.*		23,384			993,820
Mylan NV*		39,171			1,506,517
Nektar Therapeutics*		11,000			882,970
Novartis AG (Registered)		56,241			4,166,859
Novo Nordisk AS (ADR)		49,825			2,368,681
Pacira Pharmaceuticals, Inc.*		22,045			755,041
Pfizer, Inc.		227,369			8,169,368
Roche Holding AG (Genusschein)		17,483			3,748,529
Sanofi (ADR)		76,089			2,911,926
Shire PLC (ADR)		17,419			2,860,897
UCB SA		10,351			817,433
Zoetis, Inc.		46,714			3,909,962

					87,592,398
Total Common Stocks (Cost $151,039,764)					275,400,700

Securities Lending Collateral 0.8%
DWS Government & Agency Securities Portfolio “DWS Government Cash Institutional Shares”, 1.68% (b) (c) (Cost $2,154,936)		2,154,936			2,154,936

Cash Equivalents 3.1%
DWS Central Cash Management Government Fund, 1.78% (b) (Cost $8,823,902)		8,823,902			8,823,902

	% of Net Assets			Value ($)
Total Investment Portfolio (Cost $162,018,602)		100.7			286,379,538
Other Assets and Liabilities, Net		(0.7	)		(1,911,007	)

Net Assets		100.0			284,468,531

The accompanying notes are an integral part of the financial statements.


12		\|		DWS Health and Wellness Fund

A summary of the Fund’s transactions with affiliated investments during the year ended May 31, 2018 are as follows:


Value ($) at 5/31/2017		Pur- chases Cost ($)		Sales Proceeds ($)		Net Real- ized Gain/ (Loss) ($)		Net Change in Unreal- ized Appreci- ation (Depreci- ation) ($)		Income ($)		Capital Gain Distri- butions ($)		Number of Shares at 5/31/2018		Value ($) at 5/31/2018
	Securities Lending Collateral 0.8%
	DWS Government & Agency Securities Portfolio “DWS Government Cash Institutional Shares”, 1.68% (b) (c)
	11,398,924		—		9,243,988		—		—		15,389		—		2,154,936		2,154,936
	Cash Equivalents 3.1%
	DWS Central Cash Management Government Fund, 1.78% (b)
	7,738,161		60,755,195		59,669,454		—		—		83,467		—		8,823,902		8,823,902
	19,137,085		60,755,195		68,913,442		—		—		98,856		—		10,978,838		10,978,838

*	Non-income producing security.

(a)	All or a portion of these securities were on loan. In addition, “Other Assets and Liabilities, Net” may include pending sales that are also on loan. The value of securities loaned at May 31, 2018 amounted to $2,071,536, which is 0.7% of net assets.

(b)	Affiliated fund managed by DWS Investment Management Americas, Inc. The rate shown is the annualized seven-day yield at period end.

(c)	Represents collateral held in connection with securities lending. Income earned by the Fund is net of borrower rebates. Represents the net increase (purchase cost) or decrease (sales proceeds) in the amount invested for the year ended May 31, 2018.

ADR: American Depositary Receipt

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			13

Fair Value Measurements

Various inputs are used in determining the value of the Fund’s investments. These inputs are summarized in three broad levels. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.

The following is a summary of the inputs used as of May 31, 2018 in valuing the Fund’s investments. For information on the Fund’s policy regarding the valuation of investments, please refer to the Security Valuation section of Note A in the accompanying Notes to Financial Statements.


Assets	Level 1		Level 2		Level 3		Total
Common Stocks
Biotechnology	$	60,970,698	$	—	$	—	$	60,970,698
Health Care Services		59,112,837		—		—		59,112,837
Medical Supply & Specialty		66,217,132		1,507,635		—		67,724,767
Pharmaceuticals		74,656,614		12,935,784		—		87,592,398
Short-Term Investments (d)		10,978,838		—		—		10,978,838
Total	$	271,936,119	$	14,443,419	$	—	$	286,379,538

As a result of the fair valuation model utilized by the Fund, certain international securities transferred from Level 1 to Level 2. During the year ended May 31, 2018, the amount of the transfers between Level 1 and Level 2 was $14,864,906.

Transfers between price levels are recognized at the beginning of the reporting period.

(d)	See Investment Portfolio for additional detailed categorizations.

The accompanying notes are an integral part of the financial statements.


14		\|		DWS Health and Wellness Fund

Statement of Assets and Liabilities


as of May 31, 2018


Assets
Investments in non-affiliated securities, at value (cost $151,039,764) — including $2,071,536 of securities loaned	$	275,400,700
Investment in DWS Government & Agency Securities Portfolio (cost $2,154,936)*		2,154,936
Investment in DWS Central Cash Management Government Fund (cost $8,823,902)		8,823,902
Foreign currency, at value (cost $83,377)		84,483
Receivable for investments sold		571,013
Receivable for Fund shares sold		31,028
Dividends receivable		505,855
Interest receivable		13,818
Foreign taxes recoverable		209,410
Other assets		27,578
Total assets		287,822,723

Liabilities
Payable upon return of securities loaned		2,154,936
Payable for investments purchased		431,145
Payable for Fund shares redeemed		295,236
Accrued management fee		183,591
Accrued Trustees’ fees		4,254
Other accrued expenses and payables		285,030
Total liabilities		3,354,192
Net assets, at value	$	284,468,531

Net Assets Consist of
Net unrealized appreciation (depreciation) on:
Investments		124,360,936
Foreign currency		(1,506	)
Accumulated net realized gain (loss)		16,419,722
Paid-in capital		143,689,379
Net assets, at value	$	284,468,531

*	Represents collateral on securities loaned.

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			15


Statement of Assets and Liabilities as of May 31, 2018 (continued)



Net Asset Value

Class A
Net Asset Value and redemption price per share ($59,876,308 ÷ 1,664,894 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized)	$	35.96
Maximum offering price per share (100 ÷ 94.25 of $35.96)	$	38.15
Class C
Net Asset Value, offering and redemption price (subject to contingent deferred sales charge) per share ($10,778,603 ÷ 382,335 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized)	$	28.19
Class S
Net Asset Value, offering and redemption price per share ($210,464,976 ÷ 5,462,830 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized)	$	38.53
Institutional Class
Net Asset Value, offering and redemption price per share ($3,348,644 ÷ 83,499 outstanding shares of beneficial interest, $.01 par value, unlimited number of shares authorized)	$	40.10

The accompanying notes are an integral part of the financial statements.


16		\|		DWS Health and Wellness Fund

Statement of Operations


for the year ended May 31, 2018


Investment Income
Income:
Dividends (net of foreign taxes withheld of $112,304)	$	3,915,591
Income distributions — DWS Central Cash Management Government Fund		83,467
Securities lending income, net of borrower rebates		15,389
Total income		4,014,447
Expenses:
Management fee		2,289,456
Administration fee		299,275
Services to shareholders		421,721
Distribution and service fees		271,066
Custodian fee		6,339
Professional fees		95,220
Reports to shareholders		39,012
Registration fees		61,576
Trustees’ fees and expenses		16,847
Other		24,980
Total expenses before expense reductions		3,525,492
Expense reductions		(9,197	)
Total expenses after expense reductions		3,516,295
Net investment income (loss)		498,152

Realized and Unrealized Gain (Loss)
Net realized gain (loss) from:
Investments		30,420,264
Foreign currency		(17,035	)
		30,403,229
Change in net unrealized appreciation (depreciation) on:
Investments		(4,087,110	)
Foreign currency		1,300
		(4,085,810	)
Net gain (loss)		26,317,419
Net increase (decrease) in net assets resulting from operations	$	26,815,571

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			17

Statements of Changes in Net Assets


	Years Ended May 31,
Increase (Decrease) in Net Assets	2018			2017

Operations:
Net investment income (loss)	$	498,152		$	376,728
Net realized gain (loss)		30,403,229			16,863,263
Change in net unrealized appreciation (depreciation)		(4,085,810	)		1,747,560
Net increase (decrease) in net assets resulting from operations		26,815,571			18,987,551
Distributions to shareholders from:
Net investment income:
Class A		—			(11,576	)
Class S		(511,500	)		(542,110	)
Institutional Class		(6,681	)		(7,196	)
Net realized gains:
Class A		(3,980,272	)		(1,882,062	)
Class C		(904,038	)		(486,945	)
Class S		(13,116,089	)		(5,094,857	)
Institutional Class		(158,090	)		(62,832	)
Total distributions		(18,676,670	)		(8,087,578	)
Fund share transactions:
Proceeds from shares sold		17,337,603			36,809,513
Reinvestment of distributions		18,067,577			7,732,652
Payments for shares redeemed		(58,217,938	)		(102,717,784	)
Redemption fees		—			904
Net increase (decrease) in net assets from Fund share transactions		(22,812,758	)		(58,174,715	)
Increase (decrease) in net assets		(14,673,857	)		(47,274,742	)
Net assets at beginning of period		299,142,388			346,417,130
Net assets at end of period	$	284,468,531		$	299,142,388

The accompanying notes are an integral part of the financial statements.


18		\|		DWS Health and Wellness Fund

Financial Highlights


	Years Ended May 31,
Class A	2018				2017			2016			2015			2014

Selected Per Share Data
Net asset value, beginning of period		$	35.19		$	33.91		$	45.32		$	36.68		$	30.50
Income (loss) from investment operations:
Net investment income (loss)^a			.00	*		(.01	)		(.03	)		(.12	)		(.05	)
Net realized and unrealized gain (loss)			3.13			2.16			(5.08	)		12.04			8.74
Total from investment operations			3.13			2.15			(5.11	)		11.92			8.69
Less distributions from:
Net Investment income			—			(.01	)		—			—			—
Net realized gains			(2.36	)		(.86	)		(6.30	)		(3.28	)		(2.51	)
Total distributions			(2.36	)		(.87	)		(6.30	)		(3.28	)		(2.51	)
Redemption fees			—			.00	^*		.00	^*		.00	^*		.00	^*
Net asset value, end of period		$	35.96		$	35.19		$	33.91		$	45.32		$	36.68
Total Return (%)^b,c			9.01			6.62			(11.67	)		33.71			29.49

Ratios to Average Net Assets and Supplemental Data
Net assets, end of period ($ millions)			60			66			92			104			68
Ratio of expenses before expense reductions (%)			1.35			1.37			1.35			1.35			1.37
Ratio of expenses after expense reductions (%)			1.34			1.33			1.32			1.35			1.34
Ratio of net investment income (loss) (%)			.00	^*		(.03	)		(.07	)		(.30	)		(.13	)
Portfolio turnover rate (%)			27			35			56			55			33

^a	Based on average shares outstanding during the period.

^b	Total return does not reflect the effect of any sales charges.

^c	Total return would have been lower had certain expenses not been reduced.

^*	Amount is less than $.005.

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			19


	Years Ended May 31,
Class C	2018			2017			2016			2015			2014

Selected Per Share Data
Net asset value, beginning of period	$	28.25		$	27.60		$	38.44		$	31.76		$	26.89
Income (loss) from investment operations:
Net investment income (loss)^a		(.21	)		(.22	)		(.26	)		(.37	)		(.26	)
Net realized and unrealized gain (loss)		2.51			1.73			(4.28	)		10.33			7.64
Total from investment operations		2.30			1.51			(4.54	)		9.96			7.38
Less distributions from:
Net realized gains		(2.36	)		(.86	)		(6.30	)		(3.28	)		(2.51	)
Redemption fees		—			.00	^*		.00	^*		.00	^*		.00	^*
Net asset value, end of period	$	28.19		$	28.25		$	27.60		$	38.44		$	31.76
Total Return (%)^b		8.26	^c		5.82	^c		(12.33	)^c		32.72			28.54	^c

Ratios to Average Net Assets and Supplemental Data
Net assets, end of period ($ millions)		11			13			19			23			13
Ratio of expenses before expense reductions (%)		2.07			2.12			2.10			2.09			2.11
Ratio of expenses after expense reductions (%)		2.06			2.08			2.06			2.09			2.09
Ratio of net investment income (loss) (%)		(.72	)		(.79	)		(.82	)		(1.04	)		(.87	)
Portfolio turnover rate (%)		27			35			56			55			33

^a	Based on average shares outstanding during the period.

^b	Total return does not reflect the effect of any sales charges.

^c	Total return would have been lower had certain expenses not been reduced.

^*	Amount is less than $.005.

The accompanying notes are an integral part of the financial statements.


20		\|		DWS Health and Wellness Fund


	Years Ended May 31,
Class S	2018			2017			2016			2015			2014

Selected Per Share Data
Net asset value, beginning of period	$	37.53		$	36.10		$	47.70		$	38.37		$	31.73
Income (loss) from investment operations:
Net investment income (loss)^a		.10			.09			.07			(.02	)		.04
Net realized and unrealized gain (loss)		3.35			2.29			(5.37	)		12.64			9.11
Total from investment operations		3.45			2.38			(5.30	)		12.62			9.15
Less distributions from:
Net investment income		(.09	)		(.09	)		—			(.01	)		—
Net realized gains		(2.36	)		(.86	)		(6.30	)		(3.28	)		(2.51	)
Total distributions		(2.45	)		(.95	)		(6.30	)		(3.29	)		(2.51	)
Redemption fees		—			.00	^*		.00	^*		.00	^*		.00	^*
Net asset value, end of period	$	38.53		$	37.53		$	36.10		$	47.70		$	38.37
Total Return (%)		9.32			6.90			(11.47	)^b		34.07			29.80	^b

Ratios to Average Net Assets and Supplemental Data
Net assets, end of period ($ millions)		210			218			231			286			211
Ratio of expenses before expense reductions (%)		1.08			1.08			1.08			1.08			1.12
Ratio of expenses after expense reductions (%)		1.08			1.08			1.07			1.08			1.09
Ratio of net investment income (loss) (%)		.26			.24			.17			(.04	)		.11
Portfolio turnover rate (%)		27			35			56			55			33

^a	Based on average shares outstanding during the period.

^b	Total return would have been lower had certain expenses not been reduced.

^*	Amount is less than $.005.

The accompanying notes are an integral part of the financial statements.


		DWS Health and Wellness Fund		\|			21


	Years Ended May 31,
Institutional Class	2018			2017			2016			2015			2014

Selected Per Share Data
Net asset value, beginning of period		$38.97			$37.46			$49.23			$39.52			$32.62
Income (loss) from investment operations:
Net investment income (loss)^a		.13			.08			.09			(.05	)		.04
Net realized and unrealized gain (loss)		3.46			2.39			(5.56	)		13.05			9.37
Total from investment operations		3.59			2.47			(5.47	)		13.00			9.41
Less distributions from:
Net investment income		(.10	)		(.10	)		—			(.01	)		—
Net realized gains		(2.36	)		(.86	)		(6.30	)		(3.28	)		(2.51	)
Total distributions		(2.46	)		(.96	)		(6.30	)		(3.29	)		(2.51	)
Redemption fees		—			.00	^*		.00	^*		.00	^*		.00	^*
Net asset value, end of period		$40.10			$38.97			$37.46			$49.23			$39.52
Total Return (%)^b		9.30			6.91			(11.46	)		34.00			29.82

Ratios to Average Net Assets and Supplemental Data
Net assets, end of period ($ millions)		3			2			4			4			11
Ratio of expenses before expense reductions (%)		1.07			1.07			1.10			1.10			1.12
Ratio of expenses after expense reductions (%)		1.06			1.07			1.06			1.10			1.09
Ratio of net investment income (loss) (%)		.32			.20			.22			(.12	)		.11
Portfolio turnover rate (%)		27			35			56			55			33

^a	Based on average shares outstanding during the period.

^b	Total return would have been lower had certain expenses not been reduced.

^*	Amount is less than $.005.

The accompanying notes are an integral part of the financial statements.


22		\|		DWS Health and Wellness Fund


Notes to Financial Statements

A. Organization and Significant Accounting Policies

DWS Health and Wellness Fund (formerly Deutsche Health and Wellness Fund) (the “Fund”) is a diversified series of Deutsche DWS Securities Trust (formerly Deutsche Securities Trust) (the “Trust”), which is registered under the Investment Company Act of 1940, as amended (the “1940 Act”), as an open-end management investment company organized as a Massachusetts business trust.

The Fund offers multiple classes of shares which provide investors with different purchase options. Class A shares are subject to an initial sales charge. Class C shares are not subject to an initial sales charge, but are subject to higher ongoing expenses than Class A shares and a contingent deferred sales charge payable upon certain redemptions within one year of purchase. Class S shares are not subject to initial or contingent deferred sales charges and are only available to a limited group of investors. Institutional Class shares are not subject to initial or contingent deferred sales charges and are generally available only to qualified institutions.

Investment income, realized and unrealized gains and losses, and certain fund-level expenses and expense reductions, if any, are borne pro rata on the basis of relative net assets by the holders of all classes of shares, except that each class bears certain expenses unique to that class such as distribution and service fees, services to shareholders and certain other class-specific expenses. Differences in class-level expenses may result in payment of different per share dividends by class. All shares of the Fund have equal rights with respect to voting subject to class-specific arrangements.

The Fund’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) which require the use of management estimates. Actual results could differ from those estimates. The Fund qualifies as an investment company under Topic 946 of Accounting Standards Codification of U.S. GAAP. The policies described below are followed consistently by the Fund in the preparation of its financial statements.

Security Valuation. Investments are stated at value determined as of the close of regular trading on the New York Stock Exchange on each day the exchange is open for trading.


		DWS Health and Wellness Fund		\|			23

similar securities, interest rates, prepayment speeds and credit risk). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments). The level assigned to the securities valuations may not be an indication of the risk or liquidity associated with investing in those securities.

Equity securities are valued at the most recent sale price or official closing price reported on the exchange (U.S. or foreign) or over-the-counter market on which they trade. Securities for which no sales are reported are valued at the calculated mean between the most recent bid and asked quotations on the relevant market or, if a mean cannot be determined, at the most recent bid quotation. Equity securities are generally categorized as Level 1. For certain international equity securities, in order to adjust for events which may occur between the close of the foreign exchanges and the close of the New York Stock Exchange, a fair valuation model may be used. This fair valuation model takes into account comparisons to the valuation of American Depository Receipts (ADRs), exchange-traded funds, futures contracts and certain indices and these securities are categorized as Level 2.

Investments in open-end investment companies are valued at their net asset value each business day and are categorized as Level 1.

Securities and other assets for which market quotations are not readily available or for which the above valuation procedures are deemed not to reflect fair value are valued in a manner that is intended to reflect their fair value as determined in accordance with procedures approved by the Board and are generally categorized as Level 3. In accordance with the Fund’s valuation procedures, factors considered in determining value may include, but are not limited to, the type of the security; the size of the holding; the initial cost of the security; the existence of any contractual restrictions on the security’s disposition; the price and extent of public trading in similar securities of the issuer or of comparable companies; quotations or evaluated prices from broker-dealers and/or pricing services; information obtained from the issuer, analysts, and/or the appropriate stock exchange (for exchange-traded securities); an analysis of the company’s or issuer’s financial statements; an evaluation of the forces that influence the issuer and the market(s) in which the security is purchased and sold; and with respect to debt securities, the maturity, coupon, creditworthiness, currency denomination and the movement of the market in which the security is normally traded. The value determined

under these procedures may differ from published values for the same securities.

Disclosure about the classification of fair value measurements is included in a table following the Fund’s Investment Portfolio.


24		\|		DWS Health and Wellness Fund

Securities Lending. Deutsche Bank AG, as lending agent, lends securities of the Fund to certain financial institutions under the terms of its securities lending agreement. During the term of the loans, the Fund continues to receive interest and dividends generated by the securities and to participate in any changes in their market value. The Fund requires the borrowers of the securities to maintain collateral with the Fund consisting of either cash or liquid, unencumbered assets having a value at least equal to the value of the securities loaned. When the collateral falls below specified amounts, the lending agent will use its best effort to obtain additional collateral on the next business day to meet required amounts under the lending agreement. As of period end, any securities on loan were collateralized by cash. During the year ended May 31, 2018, the Fund invested the cash collateral into a joint trading account in affiliated money market funds managed by DWS Investment Management Americas, Inc. As of May 31, 2018, the Fund invested the cash collateral in DWS Government & Agency Securities Portfolio. DWS Investment Management Americas, Inc. receives a management/administration fee (0.14% annualized effective rate as of May 31, 2018) on the cash collateral invested in DWS Government & Agency Securities Portfolio. The Fund receives compensation for lending its securities either in the form of fees or by earning interest on invested cash collateral net of borrower rebates and fees paid to a lending agent. Either the Fund or the borrower may terminate the loan at any time, and the borrower, after notice, is required to return borrowed securities within a standard time period. There may be risks of delay and costs in recovery of securities or even loss of rights in the collateral should the borrower of the securities fail financially. If the Fund is not able to recover securities lent, the Fund may sell the collateral and purchase a replacement investment in the market, incurring the risk that the value of the replacement security is greater than the value of the collateral. The Fund is also subject to all investment risks associated with the reinvestment of any cash collateral received, including, but not limited to, interest rate, credit and liquidity risk associated with such investments.

As of May 31, 2018, the Fund had securities on loan, which were classified as common stock in the Investment Portfolio. The value of the related collateral exceeded the value of the securities loaned at period end. As of period end, the remaining contractual maturity of the collateral agreements were overnight and continuous.

Foreign Currency Translations. The books and records of the Fund are maintained in U.S. dollars. Investment securities and other assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the prevailing exchange rates at period end. Purchases and sales of investment securities, income and expenses are translated into U.S. dollars at the prevailing exchange rates on the respective dates of the transactions.


		DWS Health and Wellness Fund		\|			25

Net realized and unrealized gains and losses on foreign currency transactions represent net gains and losses between trade and settlement dates on securities transactions, the acquisition and disposition of foreign currencies, and the difference between the amount of net investment income accrued and the U.S. dollar amount actually received. The portion of both realized and unrealized gains and losses on investments that results from fluctuations in foreign currency exchange rates is not separately disclosed but is included with net realized and unrealized gain/appreciation and loss/depreciation on investments.

Federal Income Taxes. The Fund’s policy is to comply with the requirements of the Internal Revenue Code, as amended, which are applicable to regulated investment companies, and to distribute all of its taxable income to its shareholders.

The Fund has reviewed the tax positions for the open tax years as of May 31, 2018 and has determined that no provision for income tax and/or uncertain tax provisions is required in the Fund’s financial statements. The Fund’s federal tax returns for the prior three fiscal years remain open subject to examination by the Internal Revenue Service.

Distribution of Income and Gains. Distributions from net investment income of the Fund, if any, are declared and distributed to shareholders annually. Net realized gains from investment transactions, in excess of available capital loss carryforwards, would be taxable to the Fund if not distributed, and, therefore, will be distributed to shareholders at least annually. The Fund may also make additional distributions for tax purposes if necessary.

The timing and characterization of certain income and capital gain distributions are determined annually in accordance with federal tax regulations which may differ from accounting principles generally accepted in the United States of America. These differences primarily relate to certain securities sold at a loss. As a result, net investment income (loss) and net realized gain (loss) on investment transactions for a reporting period may differ significantly from distributions during such period. Accordingly, the Fund may periodically make reclassifications among certain of its capital accounts without impacting the net asset value of the Fund.

At May 31, 2018, the Fund’s components of distributable earnings (accumulated losses) on a tax basis were as follows:


Undistributed ordinary income*	$	652,049
Undistributed long-term capital gains	$	16,496,414
Unrealized appreciation (depreciation) on investments	$	123,632,193


26		\|		DWS Health and Wellness Fund

At May 31, 2018, the aggregate cost of investments for federal income tax purposes was $162,747,345. The net unrealized appreciation for all investments based on tax cost was $123,632,193. This consisted of aggregate gross unrealized appreciation for all investments in which there was an excess of value over tax cost of $126,689,376 and aggregate gross unrealized depreciation for all investments in which there was an excess of tax cost over value of $3,057,183.

In addition, the tax character of distributions paid to shareholders by the Fund is summarized as follows:


	Years Ended May 31,
	2018		2017
Distributions from ordinary income*	$	1,989,281	$	376,242
Distributions from long-term capital gains	$	16,687,389	$	7,711,336

*	For tax purposes, short-term capital gain distributions are considered ordinary income distributions.

Redemption Fees. Prior to February 1, 2017, the Fund imposed a redemption fee of 2% of the total redemption amount on Fund shares redeemed or exchanged within 15 days of buying them, either by purchase or exchange (subject to certain exceptions). This fee was assessed and retained by the Fund for the benefit of the remaining shareholders. The redemption fee was accounted for as an addition to paid-in capital.

Expenses. Expenses of the Trust arising in connection with a specific fund are allocated to that fund. Other Trust expenses which cannot be directly attributed to a fund are apportioned among the funds in the Trust based upon the relative net assets or other appropriate measures.

Contingencies. In the normal course of business, the Fund may enter into contracts with service providers that contain general indemnification clauses. The Fund’s maximum exposure under these arrangements is unknown, as this would involve future claims that may be made against the Fund that have not yet been made. However, based on experience, the Fund expects the risk of loss to be remote.

Other. Investment transactions are accounted for on a trade date plus one basis for daily net asset value calculations. However, for financial reporting purposes, investment transactions are reported on trade date. Interest income is recorded on the accrual basis. Dividend income is recorded on the ex-dividend date net of foreign withholding taxes. Certain dividends from foreign securities may be recorded subsequent to the ex-dividend date as soon as the Fund is informed of such dividends. Realized gains and losses from investment transactions are recorded on an identified cost basis. Proceeds from litigation payments, if any, are included in net realized gain (loss) from investments.


		DWS Health and Wellness Fund		\|			27

B. Purchases and Sales of Securities

During the year ended May 31, 2018, purchases and sales of investment securities (excluding short-term investments) aggregated $79,290,910 and $120,928,710, respectively.

C. Related Parties

Management Agreement. Under the Investment Management Agreement with DWS Investment Management Americas, Inc. (formerly Deutsche Investment Management Americas Inc.) (“DIMA” or the “Advisor”), an indirect, wholly owned subsidiary of DWS Group GmbH & Co. KGaA (“DWS Group”), the Advisor directs the investments of the Fund in accordance with its investment objectives, policies and restrictions. The Advisor determines the securities, instruments and other contracts relating to investments to be purchased, sold or entered into by the Fund.

Under the Investment Management Agreement with the Advisor, the Fund pays a monthly management fee based on the Fund’s average daily net assets, computed and accrued daily and payable monthly, at the following annual rates:


First $500 million of the Fund’s average daily net assets			.765%
Over $500 million of such net assets			.715%

Accordingly, for the year ended May 31, 2018, the fee pursuant to the Investment Management Agreement was equivalent to an annual effective rate (exclusive of any applicable waivers/reimbursements) of 0.765% of the Fund’s average daily net assets.

For the period from June 1, 2017 through September 30, 2017, the Advisor had contractually agreed to waive its fees and/or reimburse certain operating expenses of the Fund to the extent necessary to maintain the total annual operating expenses (excluding certain expenses such as extraordinary expenses, taxes, brokerage and interest) of each class as follows:


Class A			1.34%
Class C			2.09%
Class S			1.09%
Institutional Class			1.09%

Effective October 1, 2017 through September 30, 2018, the Advisor has contractually agreed to waive its fees and/or reimburse certain operating expenses of the Fund to the extent necessary to maintain the total annual


28		\|		DWS Health and Wellness Fund

operating expenses (excluding certain expenses such as extraordinary expenses, taxes, brokerage and interest) of each class as follows:


Class A			1.40%
Class C			2.15%
Class S			1.15%
Institutional Class			1.15%

For the year ended May 31, 2018, fees waived and/or expenses reimbursed for certain classes are as follows:


Class A	$	7,328
Class C		1,805
Institutional Class		64
	$	9,197

Administration Fee. Pursuant to an Administrative Services Agreement, DIMA provides most administrative services to the Fund. For all services provided under the Administrative Services Agreement, the Fund pays the Advisor an annual fee (“Administration Fee”) of 0.10% of the Fund’s average daily net assets, computed and accrued daily and payable monthly. For the year ended May 31, 2018, the Administration Fee was $299,275 of which $23,999 is unpaid.

Service Provider Fees. DWS Service Company (“DSC”), an affiliate of the Advisor, is the transfer agent, dividend-paying agent and shareholder service agent for the Fund. Pursuant to a sub-transfer agency agreement between DSC and DST Systems, Inc. (“DST”), DSC has delegated certain transfer agent, dividend-paying agent and shareholder service agent functions to DST. DSC compensates DST out of the shareholder servicing fee it receives from the Fund. For the year ended May 31, 2018, the amounts charged to the Fund by DSC were as follows:


Services to Shareholders	Total Aggregated		Unpaid at May 31, 2018
Class A	$	27,618	$	7,579
Class C		2,811		772
Class S		134,357		35,024
Institutional Class		380		124
	$	165,166	$	43,499

Distribution and Service Fees. Under the Fund’s Class C 12b-1 Plan, DWS Distributors, Inc. (“DDI”), an affiliate of the Advisor, receives a fee (“Distribution Fee”) of 0.75% of average daily net assets of Class C shares. In accordance with the Fund’s Underwriting and Distribution Services Agreement, DDI enters into related selling group agreements with various


		DWS Health and Wellness Fund		\|			29

firms at various rates for sales of Class C shares. For the year ended May 31, 2018, the Distribution Fee was as follows:


Distribution Fee	Total Aggregated		Unpaid at May 31, 2018
Class C	$	88,242	$	6,842

In addition, DDI provides information and administrative services for a fee (“Service Fee”) to Class A and C shareholders at an annual rate of up to 0.25% of average daily net assets for each such class. DDI in turn has various agreements with financial services firms that provide these services and pays these fees based upon the assets of shareholder accounts the firms service. For the year ended May 31, 2018, the Service Fee was as follows:


Service Fee	Total Aggregated		Unpaid at May 31, 2018		Annual Rate
Class A	$	153,447	$	23,779		.24	%
Class C		29,377		4,595		.25	%
	$	182,824	$	28,374

Underwriting Agreement and Contingent Deferred Sales Charge. DDI is the principal underwriter for the Fund. Underwriting commissions paid in connection with the distribution of Class A shares for the year ended May 31, 2018, aggregated $6,899.

In addition, DDI receives any contingent deferred sales charge (“CDSC”) from Class C share redemptions occurring within one year of purchase. There is no such charge upon redemption of any share appreciation or reinvested dividends. The CDSC is 1% of the value of the shares redeemed for Class C. For the year ended May 31, 2018, the CDSC for Class C shares aggregated $402. A deferred sales charge of up to 1% is assessed on certain redemptions of Class A shares. For the year ended May 31, 2018, DDI received $1,153 for Class A shares.

Typesetting and Filing Service Fees. Under an agreement with DIMA, DIMA is compensated for providing certain pre-press and regulatory filing services to the Fund. For the year ended May 31, 2018, the amount charged to the Fund by DIMA included in the Statement of Operations under “Reports to shareholders” aggregated $17,294, of which $6,532 is unpaid.

Trustees’ Fees and Expenses. The Fund paid retainer fees to each Trustee not affiliated with the Advisor, plus specified amounts to the Board Chairperson and Vice Chairperson and to each committee Chairperson.

Affiliated Cash Management Vehicles. The Fund may invest uninvested cash balances in DWS Central Cash Management Government Fund and DWS Variable NAV Money Fund, affiliated money market funds which are managed by the Advisor. Each affiliated money market fund is managed


30		\|		DWS Health and Wellness Fund

in accordance with Rule 2a-7 under the 1940 Act, which governs the quality, maturity, diversity and liquidity of instruments in which a money market fund may invest. DWS Central Cash Management Government Fund seeks to maintain a stable net asset value, and DWS Variable NAV Money Fund maintains a floating net asset value. The Fund indirectly bears its proportionate share of the expenses of each affiliated money market fund in which it invests. DWS Central Cash Management Government Fund does not pay the Advisor an investment management fee. To the extent that DWS Variable NAV Money Fund pays an investment management fee to the Advisor, the Advisor will waive an amount of the investment management fee payable to the Advisor by the Fund equal to the amount of the investment management fee payable on the Fund’s assets invested in DWS Variable NAV Money Fund.

Security Lending Fees. Deutsche Bank AG serves as securities lending agent for the Fund. For the year ended May 31, 2018, the Fund incurred securities lending agent fees to Deutsche Bank AG in the amount of $1,158.

D. Line of Credit

The Fund and other affiliated funds (the “Participants”) share in a $400 million revolving credit facility provided by a syndication of banks. The Fund may borrow for temporary or emergency purposes, including the meeting of redemption requests that otherwise might require the untimely disposition of securities. The Participants are charged an annual commitment fee which is allocated based on net assets, among each of the Participants. Interest is calculated at a rate per annum equal to the sum of the Federal Funds Rate plus 1.25 percent plus if the one-month LIBOR exceeds the Federal Funds Rate, the amount of such excess. The Fund may borrow up to a maximum of 33 percent of its net assets under the agreement. The Fund had no outstanding loans at May 31, 2018.

E. Fund Share Transactions

The following table summarizes share and dollar activity in the Fund:


	Year Ended May 31, 2018				Year Ended May 31, 2017
	Shares		Dollars		Shares		Dollars

Shares sold
Class A		150,823	$	5,505,796		263,928	$	9,027,216
Class C		19,267		556,715		60,481		1,627,126
Class S		242,759		9,512,452		691,838		25,088,462
Institutional Class		43,581		1,762,640		28,323		1,066,709
			$	17,337,603			$	36,809,513


		DWS Health and Wellness Fund		\|			31


	Year Ended May 31, 2018						Year Ended May 31, 2017
	Shares			Dollars			Shares			Dollars

Shares issued to shareholders in reinvestment of distributions
Class A		109,958		$	3,885,926			57,478		$	1,816,880
Class C		31,483			874,900			16,182			412,158
Class S		347,579			13,141,980			161,329			5,433,586
Institutional Class		4,187			164,771			2,002			70,028
				$	18,067,577					$	7,732,652

Shares redeemed
Class A		(461,238	)	$	(16,783,825	)		(1,162,953	)	$	(39,337,311	)
Class C		(120,497	)		(3,504,786	)		(323,092	)		(8,786,046	)
Class S		(944,477	)		(36,863,248	)		(1,437,661	)		(51,522,207	)
Institutional Class		(26,390	)		(1,066,079	)		(81,969	)		(3,072,220	)
				$	(58,217,938	)				$	(102,717,784	)

Redemption fees				$	—					$	904

Net increase (decrease)
Class A		(200,457	)	$	(7,392,103	)		(841,547	)	$	(28,492,804	)
Class C		(69,747	)		(2,073,171	)		(246,429	)		(6,746,760	)
Class S		(354,139	)		(14,208,816	)		(584,494	)		(20,999,669	)
Institutional Class		21,378			861,332			(51,644	)		(1,935,482	)
				$	(22,812,758	)				$	(58,174,715	)

F. Name Changes

In connection with adoption of the DWS brand, effective July 2, 2018, Deutsche Investment Management Americas Inc., the Advisor, was renamed to DWS Investment Management Americas, Inc. In addition, the “Deutsche Funds” became known as the “DWS Funds.” As a result, Deutsche Health and Wellness Fund was renamed DWS Health and Wellness Fund.


32		\|		DWS Health and Wellness Fund

Report of Independent Registered

Public Accounting Firm

To the Board of Trustees of Deutsche DWS Securities Trust and Shareholders of DWS Health and Wellness Fund

Opinion on the Financial Statements

We have audited the accompanying statement of assets and liabilities, including the investment portfolio, of DWS Health and Wellness Fund (one of the funds constituting Deutsche DWS Securities Trust, referred to hereafter as the “Fund”) as of May 31, 2018, the related statement of operations for the year ended May 31, 2018, the statements of changes in net assets for each of the two years in the period ended May 31, 2018, including the related notes, and the financial highlights for each of the five years in the period ended May 31, 2018 (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund as of May 31, 2018, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period ended May 31, 2018 and the financial highlights for each of the five years in the period ended May 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements are the responsibility of the Fund’s management. Our responsibility is to express an opinion on the Fund’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.


		DWS Health and Wellness Fund		\|			33

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of May 31, 2018 by correspondence with the custodian, transfer agent and brokers; when replies were not received from brokers, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

PricewaterhouseCoopers LLP

Boston, Massachusetts

July 24, 2018

We have served as the auditor of one or more investment companies in the DWS family of funds since 1930.


34		\|		DWS Health and Wellness Fund

Information About Your Fund’s Expenses

As an investor of the Fund, you incur two types of costs: ongoing expenses and transaction costs. Ongoing expenses include management fees, distribution and service (12b-1) fees and other Fund expenses. Examples of transaction costs include sales charges (loads), redemption fees and account maintenance fees, which are not shown in this section. The following tables are intended to help you understand your ongoing expenses (in dollars) of investing in the Fund and to help you compare these expenses with the ongoing expenses of investing in other mutual funds. The example in the table is based on an investment of $1,000 invested at the beginning of the six-month period and held for the entire period (December 1, 2017 to May 31, 2018).

The tables illustrate your Fund’s expenses in two ways:

–

Actual Fund Return. This helps you estimate the actual dollar amount of ongoing expenses (but not transaction costs) paid on a $1,000 investment in the Fund using the Fund’s actual return during the period. To estimate the expenses you paid over the period, simply divide your account value by $1,000 (for example, an $8,600 account value divided by $1,000 = 8.6), then multiply the result by the number in the “Expenses Paid per $1,000” line under the share class you hold.

–

Hypothetical 5% Fund Return. This helps you to compare your Fund’s ongoing expenses (but not transaction costs) with those of other mutual funds using the Fund’s actual expense ratio and a hypothetical rate of return of 5% per year before expenses. Examples using a 5% hypothetical fund return may be found in the shareholder reports of other mutual funds. The hypothetical account values and expenses may not be used to estimate the actual ending account balance or expenses you paid for the period.

Please note that the expenses shown in these tables are meant to highlight your ongoing expenses only and do not reflect any transaction costs. The “Expenses Paid per $1,000” line of the tables is useful in comparing ongoing expenses only and will not help you determine the relative total expense of owning different funds. Subject to certain exceptions, an account maintenance fee of $20.00 assessed once per calendar year for Classes A, C and S shares may apply for accounts with balances less than $10,000. This fee is not included in these tables. If it was, the estimate of expenses paid for Classes A, C and S shares during the period would be higher, and account value during the period would be lower, by this amount.


		DWS Health and Wellness Fund		\|			35


Expenses and Value of a $1,000 Investment for the six months ended May 31, 2018 (Unaudited)

Actual Fund Return	Class A		Class C		Class S		Institutional Class
Beginning Account Value 12/1/17	$	1,000.00	$	1,000.00	$	1,000.00	$	1,000.00
Ending Account Value 5/31/18	$	1,016.20	$	1,012.70	$	1,017.80	$	1,017.80
Expenses Paid per $1,000*	$	6.79	$	10.24	$	5.48	$	5.28

Hypothetical 5% Fund Return
Beginning Account Value 12/1/17	$	1,000.00	$	1,000.00	$	1,000.00	$	1,000.00
Ending Account Value 5/31/18	$	1,018.20	$	1,014.76	$	1,019.50	$	1,019.70
Expenses Paid per $1,000*	$	6.79	$	10.25	$	5.49	$	5.29

*	Expenses are equal to the Fund’s annualized expense ratio for each share class, multiplied by the average account value over the period, multiplied by 182 (the number of days in the most recent six-month period), then divided by 365.


Annualized Expense Ratios	Class A			Class C			Class S			Institutional Class
DWS Health and Wellness Fund		1.35	%		2.04	%		1.09	%		1.05	%

For more information, please refer to the Fund’s prospectus.

For an analysis of the fees associated with an investment in the Fund or similar funds, please refer to http://apps.finra.org/fundanalyzer/1/fa.aspx.


Tax Information		(Unaudited)

The Fund paid distributions of $2.17 per share from net long-term capital gains during its year ended May 31, 2018.

Pursuant to Section 852 of the Internal Revenue Code, the Fund designates $30,549,000 as capital gain dividends for its year ended May 31, 2018.

For corporate shareholders, 100% of the ordinary dividends (i.e., income dividends plus short-term capital gains) paid during the Fund’s fiscal year ended May 31, 2018, qualified for the dividends received deduction.

For federal income tax purposes, the Fund designates approximately $4,432,000, or the maximum amount allowable under tax law, as qualified dividend income.

Please consult a tax advisor if you have questions about federal or state income tax laws, or on how to prepare your tax returns. If you have specific questions about your account, please call (800) 728-3337.


36		\|		DWS Health and Wellness Fund

Advisory Agreement Board Considerations and Fee Evaluation

The Board of Trustees (hereinafter referred to as the “Board” or “Trustees”) approved the renewal of Deutsche Health and Wellness Fund’s (the “Fund”) investment management agreement (the “Agreement”) with Deutsche Investment Management Americas Inc. (“DIMA”) in September 2017.

In terms of the process that the Board followed prior to approving the Agreement, shareholders should know that:

–	During the entire process, all of the Fund’s Trustees were independent of DIMA and its affiliates (the “Independent Trustees”).

–

The Board met frequently during the past year to discuss fund matters and dedicated a substantial amount of time to contract review matters. Over the course of several months, the Board’s Contract Committee reviewed extensive materials received from DIMA, independent third parties and independent counsel. These materials included an analysis of the Fund’s performance, fees and expenses, and profitability from a fee consultant retained by the Fund’s Independent Trustees (the “Fee Consultant”). Based on its evaluation of the information provided, the Contract Committee presented its findings and recommendations to the Board. The Board then reviewed the Contract Committee’s findings and recommendations.

–	The Board also received extensive information throughout the year regarding performance of the Fund.

–

The Independent Trustees regularly met privately with counsel to discuss contract review and other matters. In addition, the Independent Trustees were advised by the Fee Consultant in the course of their review of the Fund’s contractual arrangements and considered a comprehensive report prepared by the Fee Consultant in connection with their deliberations.

–	In connection with reviewing the Agreement, the Board also reviewed the terms of the Fund’s Rule 12b-1 plan, distribution agreement, administrative services agreement, transfer agency agreement and other material service agreements.

In connection with the contract review process, the Contract Committee and the Board considered the factors discussed below, among others. The Board also considered that DIMA and its predecessors have managed the Fund since its inception, and the Board believes that a long-term relationship with a capable, conscientious advisor is in the best interests


		DWS Health and Wellness Fund		\|			37

of the Fund. The Board considered, generally, that shareholders chose to invest or remain invested in the Fund knowing that DIMA managed the Fund and that the Agreement was approved by the Fund’s shareholders. DIMA is part of Deutsche Bank AG’s (“Deutsche Bank”) Asset Management (“Deutsche AM”) division. Deutsche AM is a global asset management business that offers a wide range of investing expertise and resources, including research capabilities in many countries throughout the world.

As part of the contract review process, the Board carefully considered the fees and expenses of each Deutsche fund overseen by the Board in light of the fund’s performance. In many cases, this led to the negotiation and implementation of expense caps. As part of these negotiations, the Board indicated that it would consider relaxing these caps in future years following sustained improvements in performance, among other considerations.

While shareholders may focus primarily on fund performance and fees, the Fund’s Board considers these and many other factors, including the quality and integrity of DIMA’s personnel and administrative support services provided by DIMA, such as back-office operations, fund valuations, and compliance policies and procedures.

Nature, Quality and Extent of Services. The Board considered the terms of the Agreement, including the scope of advisory services provided under the Agreement. The Board noted that, under the Agreement, DIMA provides portfolio management services to the Fund and that, pursuant to a separate administrative services agreement, DIMA provides administrative services to the Fund. The Board considered the experience and skills of senior management and investment personnel and the resources made available to such personnel. The Board reviewed the Fund’s performance over short-term and long-term periods and compared those returns to various agreed-upon performance measures, including market index(es) and a peer universe compiled using information supplied by Morningstar Direct (“Morningstar”), an independent fund data service. The Board also noted that it has put into place a process of identifying “Funds in Review” (e.g., funds performing poorly relative to a peer universe), and receives additional reporting from DIMA regarding such funds and, where appropriate, DIMA’s plans to address underperformance. The Board believes this process is an effective manner of identifying and addressing underperforming funds. Based on the information provided, the Board noted that, for the one-, three- and five-year periods ended December 31, 2016, the Fund’s performance (Class A shares) was in the 3rd quartile of the applicable Morningstar universe (the 1st quartile being the best performers and the 4th quartile being the worst performers). The Board also observed that the Fund has


38		\|		DWS Health and Wellness Fund

outperformed its benchmark in the three- and five-year periods and has underperformed its benchmark in the one-year period ended December 31, 2016.

Fees and Expenses. The Board considered the Fund’s investment management fee schedule, operating expenses and total expense ratios, and comparative information provided by Broadridge Financial Solutions, Inc. (“Broadridge”) and the Fee Consultant regarding investment management fee rates paid to other investment advisors by similar funds (1st quartile being the most favorable and 4th quartile being the least favorable). With respect to management fees paid to other investment advisors by similar funds, the Board noted that the contractual fee rates paid by the Fund, which include a 0.10% fee paid to DIMA under the Fund’s administrative services agreement, were higher than the median (3rd quartile) of the applicable Broadridge peer group (based on Broadridge data provided as of December 31, 2016). The Board noted that the Fund’s Class A shares total (net) operating expenses (excluding 12b-1 fees) were expected to be higher than the median (3rd quartile) of the applicable Broadridge expense universe (based on Broadridge data provided as of December 31, 2016, and analyzing Broadridge expense universe Class A (net) expenses less any applicable 12b-1 fees) (“Broadridge Universe Expenses”). The Board also reviewed data comparing each share class’s total (net) operating expenses to the applicable Broadridge Universe Expenses. The Board noted that the expense limitations agreed to by DIMA were expected to help the Fund’s total (net) operating expenses remain competitive. The Board considered the Fund’s management fee rate as compared to fees charged by DIMA to a comparable Deutsche U.S. registered fund (“Deutsche Funds”) and considered differences between the Fund and the comparable Deutsche Fund. The information requested by the Board as part of its review of fees and expenses also included information about institutional accounts (including any sub-advised funds and accounts) and funds offered primarily to European investors (“Deutsche Europe funds”) managed by Deutsche AM. The Board noted that DIMA indicated that Deutsche AM does not manage any institutional accounts or Deutsche Europe funds comparable to the Fund.

On the basis of the information provided, the Board concluded that management fees were reasonable and appropriate in light of the nature, quality and extent of services provided by DIMA.

Profitability. The Board reviewed detailed information regarding revenues received by DIMA under the Agreement. The Board considered the estimated costs to DIMA, and pre-tax profits realized by DIMA, from advising the Deutsche Funds, as well as estimates of the pre-tax profits attributable to managing the Fund in particular. The Board also received information regarding the estimated enterprise-wide profitability of DIMA


		DWS Health and Wellness Fund		\|			39

and its affiliates with respect to all fund services in totality and by fund. The Board and the Fee Consultant reviewed DIMA’s methodology in allocating its costs to the management of the Fund. Based on the information provided, the Board concluded that the pre-tax profits realized by DIMA in connection with the management of the Fund were not unreasonable. The Board also reviewed certain publicly available information regarding the profitability of certain similar investment management firms. The Board noted that, while information regarding the profitability of such firms is limited (and in some cases is not necessarily prepared on a comparable basis), DIMA and its affiliates’ overall profitability with respect to the Deutsche Funds (after taking into account distribution and other services provided to the funds by DIMA and its affiliates) was lower than the overall profitability levels of most comparable firms for which such data was available.

Economies of Scale. The Board considered whether there are economies of scale with respect to the management of the Fund and whether the Fund benefits from any economies of scale. The Board noted that the Fund’s investment management fee schedule includes fee breakpoints. The Board concluded that the Fund’s fee schedule represents an appropriate sharing between the Fund and DIMA of such economies of scale as may exist in the management of the Fund at current asset levels.

Other Benefits to DIMA and Its Affiliates. The Board also considered the character and amount of other incidental benefits received by DIMA and its affiliates, including any fees received by DIMA for administrative services provided to the Fund, any fees received by an affiliate of DIMA for transfer agency services provided to the Fund and any fees received by an affiliate of DIMA for distribution services. The Board also considered benefits to DIMA related to brokerage and soft-dollar allocations, including allocating brokerage to pay for research generated by parties other than the executing broker dealers, which pertain primarily to funds investing in equity securities. In addition, the Board considered the incidental public relations benefits to DIMA related to Deutsche Funds advertising and cross-selling opportunities among DIMA products and services. The Board considered these benefits in reaching its conclusion that the Fund’s management fees were reasonable.

Compliance. The Board considered the significant attention and resources dedicated by DIMA to documenting and enhancing its compliance processes in recent years. The Board noted in particular (i) the experience, seniority and time commitment of the individuals serving as DIMA’s and the Fund’s chief compliance officers; (ii) the large number of DIMA compliance personnel; and (iii) the substantial commitment of resources by DIMA and its affiliates to compliance matters.

Based on all of the information considered and the conclusions reached, the Board unanimously determined that the continuation of


40		\|		DWS Health and Wellness Fund

the Agreement is in the best interests of the Fund. In making this determination, the Board did not give particular weight to any single factor identified above. The Board considered these factors over the course of numerous meetings, certain of which were in executive session with only the Independent Trustees and counsel present. It is possible that individual Independent Trustees may have weighed these factors differently in reaching their individual decisions to approve the continuation of the Agreement.


		DWS Health and Wellness Fund		\|			41

Board Members and Officers

The following table presents certain information regarding the Board Members and Officers of the Fund. Each Board Member’s year of birth is set forth in parentheses after his or her name. Unless otherwise noted, (i) each Board Member has engaged in the principal occupation(s) noted in the table for at least the most recent five years, although not necessarily in the same capacity; and (ii) the address of each Independent Board Member is c/o Keith R. Fox, DWS Funds Board Chair, c/o Thomas R. Hiller, Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199-3600. Except as otherwise noted below, the term of office for each Board Member is until the election and qualification of a successor, or until such Board Member sooner dies, resigns, is removed or as otherwise provided in the governing documents of the Fund. Because the Fund does not hold an annual meeting of shareholders, each Board Member will hold office for an indeterminate period. The Board Members may also serve in similar capacities with other funds in the fund complex.


Independent Board Members
Name, Year of Birth, Position with the Fund and Length of Time Served¹	Business Experience and Directorships During the Past Five Years	Number of Funds in DWS Fund Complex Overseen		Other Directorships Held by Board Member
Keith R. Fox, CFA (1954) Chairperson since 2017, and Board Member since 1996	Managing General Partner, Exeter Capital Partners (a series of private investment funds) (since 1986). Directorships: Progressive International Corporation (kitchen goods importer and distributor); The Kennel Shop (retailer); former Chairman, National Association of Small Business Investment Companies; former Directorships: BoxTop Media Inc. (advertising); Sun Capital Advisers Trust (mutual funds) (2011–2012)		87	—
John W. Ballantine (1946) Board Member since 1999	Retired; formerly, Executive Vice President and Chief Risk Management Officer, First Chicago NBD Corporation/The First National Bank of Chicago (1996–1998); Executive Vice President and Head of International Banking (1995–1996); former Directorships: Director and former Chairman of the Board, Healthways, Inc.² (population well-being and wellness services) (2003–2014); Stockwell Capital Investments PLC (private equity); Enron Corporation; FNB Corporation; Tokheim Corporation; First Oak Brook Bancshares, Inc. and Oak Brook Bank; Prisma Energy International. Not-for-Profit Director, Trustee: Palm Beach Civic Association; Public Radio International; Window to the World Communications (public media); Harris Theater for Music and Dance (Chicago)		87	Portland General Electric²(utility company) (2003– present)


42		\|		DWS Health and Wellness Fund


Name, Year of Birth, Position with the Fund and Length of Time Served¹	Business Experience and Directorships During the Past Five Years	Number of Funds in DWS Fund Complex Overseen		Other Directorships Held by Board Member
Henry P. Becton, Jr. (1943) Board Member since 1990	Vice Chair and former President, WGBH Educational Foundation. Directorships: Public Radio International; Public Radio Exchange (PRX); The Pew Charitable Trusts (charitable organization); Massachusetts Humane Society; American Documentary, Inc. (public media); Overseer of the New England Conservatory; former Directorships: Becton Dickinson and Company²(medical technology company); Belo Corporation²(media company); The PBS Foundation; Association of Public Television Stations; Boston Museum of Science; American Public Television; Concord Academy; New England Aquarium; Mass. Corporation for Educational Telecommunications; Committee for Economic Development; Public Broadcasting Service; Connecticut College; North Bennett Street School (Boston)		87	—
Dawn-Marie Driscoll (1946) Board Member since 1987	Emeritus Executive Fellow, Center for Business Ethics, Bentley University; formerly: President, Driscoll Associates (consulting firm); Partner, Palmer & Dodge (law firm) (1988–1990); Vice President of Corporate Affairs and General Counsel, Filene’s (retail) (1978–1988). Directorships: Advisory Board, Center for Business Ethics, Bentley University; Trustee and former Chairman of the Board, Southwest Florida Community Foundation (charitable organization); former Directorships: ICI Mutual Insurance Company (2007–2015); Sun Capital Advisers Trust (mutual funds) (2007–2012), Investment Company Institute (audit, executive, nominating committees) and Independent Directors Council (governance, executive committees)		87	—
Paul K. Freeman (1950) Board Member since 1993	Consultant, World Bank/Inter-American Development Bank; Independent Directors Council (former chair); Investment Company Institute (executive committee); Adjunct Professor, University of Denver Law School (2017–present); formerly: Chairman of Education Committee of Independent Directors Council; Project Leader, International Institute for Applied Systems Analysis (1998–2001); Chief Executive Officer, The Eric Group, Inc. (environmental insurance) (1986–1998); Directorships: Knoebel Institute for Healthy Aging, University of Denver (2017–present); former Directorships: Prisma Energy International; Denver Zoo Foundation (2012–2018)		87	—


		DWS Health and Wellness Fund		\|			43


Name, Year of Birth, Position with the Fund and Length of Time Served¹	Business Experience and Directorships During the Past Five Years	Number of Funds in DWS Fund Complex Overseen		Other Directorships Held by Board Member
Richard J. Herring (1946) Board Member since 1990	Jacob Safra Professor of International Banking and Professor, Finance Department, The Wharton School, University of Pennsylvania (since July 1972); Co-Director, Wharton Financial Institutions Center; formerly: Vice Dean and Director, Wharton Undergraduate Division (July 1995–June 2000); Director, Lauder Institute of International Management Studies (July 2000–June 2006)		87	Director, Aberdeen Singapore and Japan Funds (since 2007); Independent Director of Barclays Bank Delaware (since September 2010)
William McClayton (1944) Board Member since 2004	Private equity investor (since October 2009); previously, Managing Director, Diamond Management & Technology Consultants, Inc. (global consulting firm) (2001–2009); Directorship: Board of Managers, YMCA of Metropolitan Chicago; formerly: Senior Partner, Arthur Andersen LLP (accounting) (1966–2001); Trustee, Ravinia Festival		87	—
Rebecca W. Rimel (1951) Board Member since 1995	President, Chief Executive Officer and Director, The Pew Charitable Trusts (charitable organization) (1994–present); formerly: Executive Vice President, The Glenmede Trust Company (investment trust and wealth management) (1983–2004); Board Member, Investor Education (charitable organization) (2004–2005); Trustee, Executive Committee, Philadelphia Chamber of Commerce (2001–2007); Director, Viasys Health Care² (January 2007–June 2007); Trustee, Thomas Jefferson Foundation (charitable organization) (1994–2012)		87	Director, Becton Dickinson and Company² (medical technology company) (2012– present); Director, BioTelemetry Inc.²(health care) (2009– present)
William N. Searcy, Jr. (1946) Board Member since 1993	Private investor since October 2003; formerly: Pension & Savings Trust Officer, Sprint Corporation²(telecommunications) (November 1989–September 2003); Trustee, Sun Capital Advisers Trust (mutual funds) (1998–2012)		87	—


44		\|		DWS Health and Wellness Fund

Name, Year of
Birth, Position
with the Fund
and Length of
Time Served¹

Business Experience and Directorships
During the Past Five Years

Number of
Funds in
DWS Fund
Complex
Overseen

Other
Directorships
Held by Board
Member

Jean Gleason Stromberg (1943)

Board Member since 1997

Retired. Formerly, Consultant (1997–2001); Director, Financial Markets U.S. Government Accountability Office (1996–1997); Partner, Norton Rose Fulbright, L.L.P. (law firm) (1978–1996); former Directorships: The William and Flora Hewlett Foundation (charitable organization) (2000–2015); Service Source, Inc. (nonprofit), Mutual Fund Directors Forum (2002–2004), American Bar Retirement Association (funding vehicle for retirement plans) (1987–1990 and 1994–1996)

—


Officers⁴
Name, Year of Birth, Position with the Fund and Length of Time Served⁵		Business Experience and Directorships During the Past Five Years
Hepsen Uzcan^{6, 9}(1974) President and Chief Executive Officer, 2017–present Assistant Secretary, 2013–present		Managing Director³, DWS; Secretary and Managing Director³, DWS USA Corporation (since March 2018); Assistant Secretary, DWS Distributors, Inc. (since June 25, 2018); Director and Vice President, DWS Service Company (since June 25, 2018); Assistant Secretary, DWS Investment Management Americas, Inc. (since June 25, 2018); and Director and President, DB Investment Managers, Inc. (since June 25, 2018); formerly: Vice President for the Deutsche funds (2016–2017)
John Millette⁸(1962) Vice President and Secretary, 1999–present		Director,³DWS; Chief Legal Officer, DWS Investment Management Americas, Inc. (2015–present); and Director and Vice President, DWS Trust Company (2016–present); formerly: Secretary, Deutsche Investment Management Americas Inc. (2015–2017)
Diane Kenneally^{8, 10} (1966) Treasurer and Chief Financial Officer since 2018		Director³, DWS; formerly: Assistant Treasurer for the DWS funds (2007-2018)
Caroline Pearson⁸(1962) Chief Legal Officer, 2010–present		Managing Director,³DWS; formerly: Secretary, Deutsche AM Distributors, Inc. (2002–2017); and Secretary, Deutsche AM Service Company (2010–2017)
Scott D. Hogan⁸(1970) Chief Compliance Officer, 2016–present		Director,³DWS
Wayne Salit⁷(1967) Anti-Money Laundering Compliance Officer, 2014–present		Director³, Deutsche Bank; and AML Officer, DWS Trust Company; formerly: Managing Director, AML Compliance Officer at BNY Mellon (2011–2014); and Director, AML Compliance Officer at Deutsche Bank (2004–2011)
Sheila Cadogan⁸(1966) Assistant Treasurer, since July 12, 2017		Director,³DWS; Director and Vice President, DWS Trust Company (since 2018)


		DWS Health and Wellness Fund		\|			45

Name, Year of Birth,
Position with the Fund and
Length of Time Served⁵

Business Experience and Directorships During the Past
Five Years

Paul Antosca⁸(1957)

Assistant Treasurer, 2007–present

Director,³DWS

¹	The length of time served represents the year in which the Board Member joined the board of one or more DWS funds currently overseen by the Board.

²	A publicly held company with securities registered pursuant to Section 12 of the Securities Exchange Act of 1934.

³	Executive title, not a board directorship.

⁴	As a result of their respective positions held with the Advisor or its affiliates, these individuals are considered “interested persons” of the Advisor within the meaning of the 1940 Act. Interested persons receive no compensation from the Fund.

⁵	The length of time served represents the year in which the officer was first elected in such capacity for one or more DWS funds.

⁶	Address: 345 Park Avenue, New York, NY 10154.

⁷	Address: 60 Wall Street, New York, NY 10005.

⁸	Address: One International Place, Boston, MA 02110.

⁹	Appointed President and Chief Executive Officer effective December 1, 2017.

¹⁰	Appointed Treasurer and Chief Financial Officer effective July 2, 2018.

The Fund’s Statement of Additional Information (“SAI”) includes additional information about the Board Members. The SAI is available, without charge, upon request. If you would like to request a copy of the SAI, you may do so by calling the following toll-free number: (800) 728-3337.


46		\|		DWS Health and Wellness Fund

Account Management Resources


For More Information		The automated telephone system allows you to access personalized account information and obtain information on other DWS funds using either your voice or your telephone keypad. Certain account types within Classes A, C and S also have the ability to purchase, exchange or redeem shares using this system. For more information, contact your financial advisor. You may also access our automated telephone system or speak with a Shareholder Service representative by calling: (800) 728-3337
Web Site		dws.com View your account transactions and balances, trade shares, monitor your asset allocation, subscribe to fund and account updates by e-mail, and change your address, 24 hours a day. Obtain prospectuses and applications, news about DWS funds, insight from DWS economists and investment specialists and access to DWS fund account information.
Written Correspondence		DWS PO Box 219151 Kansas City, MO 64121-9151
Proxy Voting		The Fund’s policies and procedures for voting proxies for portfolio securities and information about how the Fund voted proxies related to its portfolio securities during the most recent 12-month period ended June 30 are available on our Web site — dws.com/en-us/resources/proxy-voting — or on the SEC’s Web site — sec.gov. To obtain a written copy of the Fund’s policies and procedures without charge, upon request, call us toll free at (800) 728-3337.
Portfolio Holdings		Following the Fund’s fiscal first and third quarter-end, a complete portfolio holdings listing is filed with the SEC on Form N-Q. This form will be available on the SEC’s Web site at sec.gov, and it also may be reviewed and copied at the SEC’s Public Reference Room in Washington, D.C. Information on the operation of the SEC’s Public Reference Room may be obtained by calling (800) SEC-0330. The Fund’s portfolio holdings are also posted on dws.com from time to time. Please see the Fund’s current prospectus for more information.
Principal Underwriter		If you have questions, comments or complaints, contact: DWS Distributors, Inc. 222 South Riverside Plaza Chicago, IL 60606-5808 (800) 621-1148


		DWS Health and Wellness Fund		\|			47


Investment Management	DWS Investment Management Americas, Inc. (“DIMA” or the “Advisor”), which is part of the DWS Group GmbH & Co. KGaA (“DWS Group”), is the investment advisor for the Fund. DIMA and its predecessors have more than 90 years of experience managing mutual funds and DIMA provides a full range of investment advisory services to both institutional and retail clients. DIMA is an indirect, wholly owned subsidiary of DWS Group. DWS Group is a global organization that offers a wide range of investing expertise and resources, including hundreds of portfolio managers and analysts and an office network that reaches the world’s major investment centers. This well-resourced global investment platform brings together a wide variety of experience and investment insight across industries, regions, asset classes and investing styles.

	Class A	Class C	Class S	Institutional Class
Nasdaq Symbol	SUHAX	SUHCX	SCHLX	SUHIX
CUSIP Number	25159L 620	25159L 596	25159L 588	25159L 570
Fund Number	452	752	2352	1452


48		\|		DWS Health and Wellness Fund

LOGO

DHWF-2

(R-027917-7 7/18)


ITEM 2.	CODE OF ETHICS

	As of the end of the period covered by this report, the registrant has adopted a code of ethics, as defined in Item 2 of Form N-CSR that applies to its Principal Executive Officer and Principal Financial Officer. There have been no amendments to, or waivers from, a provision of the code of ethics during the period covered by this report that would require disclosure under Item 2. A copy of the code of ethics is filed as an exhibit to this Form N-CSR.

ITEM 3.	AUDIT COMMITTEE FINANCIAL EXPERT

	The fund’s audit committee is comprised solely of trustees who are "independent" (as such term has been defined by the Securities and Exchange Commission ("SEC") in regulations implementing Section 407 of the Sarbanes-Oxley Act (the "Regulations")). The fund’s Board of Trustees has determined that there are several "audit committee financial experts" (as such term has been defined by the Regulations) serving on the fund’s audit committee including Mr. Paul K. Freeman, the chair of the fund’s audit committee. An “audit committee financial expert” is not an “expert” for any purpose, including for purposes of Section 11 of the Securities Act of 1933 and the designation or identification of a person as an “audit committee financial expert” does not impose on such person any duties, obligations or liability that are greater than the duties, obligations and liability imposed on such person as a member of the audit committee and board of directors in the absence of such designation or identification.

ITEM 4.	PRINCIPAL ACCOUNTANT FEES AND SERVICES

dWS Health and Wellness Fund
form n-csr disclosure re: AUDIT FEES

The following table shows the amount of fees that PricewaterhouseCoopers, LLP (“PWC”), the Fund’s independent registered public accounting firm, billed to the Fund during the Fund’s last two fiscal years. The Audit Committee approved in advance all audit services and non-audit services that PWC provided to the Fund.

Services that the Fund’s Independent Registered Public Accounting Firm Billed to the Fund

Fiscal Year Ended May 31,	Audit Fees Billed to Fund	Audit-Related Fees Billed to Fund	Tax Fees Billed to Fund	All Other Fees Billed to Fund
2018	$65,987	$0	$0	$1,500
2017	$64,285	$3,000	$0	$1,500

The “Audit Related Fees Billed to Fund” were billed for services rendered in connection with a registration filing and “All Other Fees Billed to the Fund” were billed for services associated with foreign tax filings.

Services that the Fund’s Independent Registered Public Accounting Firm Billed to the Adviser and Affiliated Fund Service Providers

The following table shows the amount of fees billed by PWC to DWS Investment Management Americas Inc. (“DIMA” or the “Adviser”), and any entity controlling, controlled by or under common control with DIMA (“Control Affiliate”) that provides ongoing services to the Fund (“Affiliated Fund Service Provider”), for engagements directly related to the Fund’s operations and financial reporting, during the Fund’s last two fiscal years.

Fiscal Year Ended March 31,	Audit-Related Fees Billed to Adviser and Affiliated Fund Service Providers	Tax Fees Billed to Adviser and Affiliated Fund Service Providers	All Other Fees Billed to Adviser and Affiliated Fund Service Providers
2018	$0	$0	$0
2017	$0	$52,339	$0

The “Tax Fees Billed to the Advisor” were billed for services associated with foreign tax filings.

Non-Audit Services

The following table shows the amount of fees that PWC billed during the Fund’s last two fiscal years for non-audit services. The Audit Committee pre-approved all non-audit services that PWC provided to the Adviser and any Affiliated Fund Service Provider that related directly to the Fund’s operations and financial reporting. The Audit Committee requested and received information from PWC about any non-audit services that PWC rendered during the Fund’s last fiscal year to the Adviser and any Affiliated Fund Service Provider. The Committee considered this information in evaluating PWC’s independence.

Fiscal Year
Ended
March 31,

Total
Non-Audit Fees Billed to Fund

(A)

Total Non-Audit Fees billed to Adviser and Affiliated Fund Service Providers (engagements related directly to the operations and financial reporting of the Fund)

(B)

Total Non-Audit Fees billed to Adviser and Affiliated Fund Service Providers (all other engagements)

(C)

Total of (A), (B)

and (C)

2018

$1,500

2017

$1,500

$52,339

$53,839

Audit Committee Pre-Approval Policies and Procedures. Generally, each Fund’s Audit Committee must pre approve (i) all services to be performed for a Fund by a Fund’s Independent Registered Public Accounting Firm and (ii) all non-audit services to be performed by a Fund’s Independent Registered Public Accounting Firm for the DIMA Entities with respect to operations and financial reporting of the Fund, except that the Chairperson or Vice Chairperson of each Fund’s Audit Committee may grant the pre-approval for non-audit services described in items (i) and (ii) above for non-prohibited services for engagements of less than $100,000. All such delegated pre approvals shall be presented to each Fund’s Audit Committee no later than the next Audit Committee meeting.

There were no amounts that were approved by the Audit Committee pursuant to the de minimis exception under Rule 2-01 of Regulation S-X.

According to the registrant’s principal Independent Registered Public Accounting Firm, substantially all of the principal Independent Registered Public Accounting Firm's hours spent on auditing the registrant's financial statements were attributed to work performed by full-time permanent employees of the principal Independent Registered Public Accounting Firm.

***

In connection with the audit of the 2017 and 2018 financial statements, the Fund entered into an engagement letter with PwC. The terms of the engagement letter required by PwC, and agreed to by the Fund’s Audit Committee, include a provision mandating the use of mediation and arbitration to resolve any controversy or claim between the parties arising out of or relating to the engagement letter or the services provided there-under.

***

Pursuant to PCAOB Rule 3526, PwC is required to describe in writing to the Fund’s Audit Committee, on at least an annual basis, all relationships between PwC, or any of its affiliates, and the DWS Funds, including the Fund, or persons in financial reporting oversight roles at the DWS Funds that, as of the date of the communication, may reasonably be thought to bear on PwC’s independence. Pursuant to PCAOB Rule 3526, PwC has reported the matters set forth below that may reasonably be thought to bear on PwC’s independence. In its PCAOB Rule 3526 communications to the Audit Committee, PwC affirmed that they are independent accountants with respect to the DWS Funds, within the meaning of PCAOB Rule 3520. PwC also informed the Audit Committee that they concluded that a reasonable investor with knowledge of all relevant facts and circumstances would conclude that PwC is capable of exercising objective and impartial judgment on all issues encompassed within PwC’s audit of the financial statements of the Fund. Finally, PwC confirmed to the Audit Committee that they can continue to serve as the independent registered public accounting firm for the Fund.

PwC advised the Fund’s Audit Committee that covered persons within PwC that provided non-audit services to entities within the DWS Funds “investment company complex” (as defined in Regulation S-X) (the “DWS Funds Complex”) maintained financial relationships with investment companies within the DWS Funds Complex. PwC informed the Audit Committee that these financial relationships were inconsistent with Rule 2-01(c)(1) of Regulation S-X. PwC reported that the breaches have been resolved and that, among other things, the breaches (i) did not involve professionals who were part of the audit engagement team for the Fund or in a position to influence the audit engagement team, (ii) involved professionals whose non-audit services were not and will not be utilized or relied upon by the audit engagement team in the audit of the financial statements of the Fund and (iii) involved professionals that did not provide any consultation to the audit engagement team of the Fund.

PwC advised the Fund’s Audit Committee of certain lending relationships of PwC with owners of greater than 10% of the shares of certain investment companies within the DWS Funds Complex that PwC had identified as inconsistent with Rule 2-01(c)(l)(ii)(A) of Regulation S-X (referred to as the “Loan Rule”). The Loan Rule specifically provides that an accounting firm would not be independent if it receives a loan from a lender that is a record or beneficial owner of more than ten percent of an audit client’s equity securities. For purposes of the Loan Rule, an audit client includes the Fund as well as all other investment companies in the DWS Funds Complex. PwC’s lending relationships affect PwC’s independence under the Loan Rule with respect to all investment companies in the DWS Funds Complex.

PwC stated that, in each lending relationship, (i) PwC believes that it is unlikely the lenders would have any interest in the outcome of the audit of the Fund and therefore would not seek to influence the outcome of the audit, (ii) no third party made an attempt to influence the outcome of the audit of the Fund and even if an attempt was made, PwC professionals are required to disclose any relationships that may raise issues about objectivity, confidentiality, independence, conflicts of interest or favoritism, and (iii) the lenders typically lack influence over the investment adviser, who controls the management of the Fund. In addition, on June 20, 2016, the SEC Staff issued a “no-action” letter to another mutual fund complex, Fidelity Management & Research Company et al., SEC Staff No-Action Letter (June 20, 2016) (the “Fidelity Letter”), related to similar Loan Rule issues as those described above. In the Fidelity Letter, the SEC Staff confirmed that it would not recommend enforcement action against an investment company that relied on the audit services performed by an audit firm that was not in compliance with the Loan Rule in certain specified circumstances. With respect to each lending relationship identified by PwC, the circumstances described in the Fidelity Letter appear to be substantially similar to the circumstances that affected PwC’s independence under the Loan Rule with respect to the Fund. PwC represented that they have complied with PCAOB Rule 3526(b)(1) and (2), which are conditions to the Fund relying on the no action letter, and affirmed that they are independent accountants within the meaning of PCAOB Rule 3520.


ITEM 5.	AUDIT COMMITTEE OF LISTED REGISTRANTS

	Not applicable

ITEM 6.	SCHEDULE OF INVESTMENTS

	Not applicable

ITEM 7.	DISCLOSURE OF PROXY VOTING POLICIES AND PROCEDURES FOR CLOSED-END MANAGEMENT INVESTMENT COMPANIES

	Not applicable

ITEM 8.	PORTFOLIO MANAGERS OF CLOSED-END MANAGEMENT INVESTMENT COMPANIES

	Not applicable

ITEM 9.	PURCHASES OF EQUITY SECURITIES BY CLOSED-END MANAGEMENT INVESTMENT COMPANY AND AFFILIATED PURCHASERS

	Not applicable

ITEM 10.	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

	There were no material changes to the procedures by which shareholders may recommend nominees to the Fund’s Board. The primary function of the Nominating and Governance Committee is to identify and recommend individuals for membership on the Board and oversee the administration of the Board Governance Guidelines. Shareholders may recommend candidates for Board positions by forwarding their correspondence by U.S. mail or courier service to Keith R. Fox, DWS Funds Board Chair, c/o Thomas R. Hiller, Ropes & Gray LLP, Prudential Tower, 800 Boylston Street, Boston, MA 02199-3600.

ITEM 11.	CONTROLS AND PROCEDURES

	(a)	The Chief Executive and Financial Officers concluded that the Registrant’s Disclosure Controls and Procedures are effective based on the evaluation of the Disclosure Controls and Procedures as of a date within 90 days of the filing date of this report.

	(b)	There have been no changes in the registrant’s internal control over financial reporting that occurred during the second fiscal quarter of the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant’s internal controls over financial reporting.

ITEM 12.	Disclosure of Securities Lending Activities for Closed-End Management Investment Companies

	Not applicable

ITEM 13.	EXHIBITS

	(a)(1)	Code of Ethics pursuant to Item 2 of Form N-CSR is filed and attached hereto as EX-99.CODE ETH.

	(a)(2)	Certification pursuant to Rule 30a-2(a) under the Investment Company Act of 1940 (17 CFR 270.30a-2(a)) is filed and attached hereto as Exhibit 99.CERT.

	(b)	Certification pursuant to Rule 30a-2(b) under the Investment Company Act of 1940 (17 CFR 270.30a-2(b)) is furnished and attached hereto as Exhibit 99.906CERT.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant:	DWS Health and Wellness Fund, a series of Deutsche DWS Securities Trust


By:	/s/Hepsen Uzcan Hepsen Uzcan President

Date:	7/30/2018

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By:	/s/Hepsen Uzcan Hepsen Uzcan President

Date:	7/30/2018



By:	/s/Diane Kenneally Diane Kenneally Chief Financial Officer and Treasurer

Date:	7/30/2018

DWS

Principal Executive and Principal Financial Officer Code of Ethics

For the Registered Management Investment Companies Listed on Appendix A

Effective Date

January 31, 2005

Date Last Approved

July 11, 2018 – DWS Funds

July 27, 2018 – Germany Funds

Revised

July 2, 2018

Revised Appendix A

July 2, 2018

Table of Contents

I. Overview	3
II. Purposes of the Officer Code	3
III. Responsibilities of Covered Officers	4
A. Honest and Ethical Conduct	4
B. Conflicts of Interest	4
C. Use of Personal Fund Shareholder Information	6
D. Public Communications	6
E. Compliance with Applicable Laws, Rules and Regulations	6
IV. Violation Reporting	7
A. Overview	7
B. How to Report	7
C. Process for Violation Reporting to the Fund Board	7
D. Sanctions for Code Violations	7
V. Waivers from the Officer Code	8
VI. Amendments to the Code	8
VII. Acknowledgement and Certification of Adherence to the Officer Code	8
IX. Recordkeeping	9
X. Confidentiality	9
Appendices	10
Appendix A: List of Officers Covered under the Code, by Board	10
Appendix B: Officer Code Acknowledgement and Certification Form	11
Appendix C: Definitions	13

Overview

This Principal Executive Officer and Principal Financial Officer Code of Ethics (“Officer Code”) sets forth the policies, practices, and values expected to be exhibited in the conduct of the Principal Executive Officers and Principal Financial Officers of the investment companies (each a “Fund” and together, the “Funds”) they serve (“Covered Officers”). A list of Covered Officers and Funds is included on Appendix A.

The Boards of the Funds listed on Appendix A have elected to implement the Officer Code, pursuant to Section 406 of the Sarbanes-Oxley Act of 2002 and the SEC’s rules thereunder, to promote and demonstrate honest and ethical conduct in their Covered Officers.

DWS represents the asset management activities conducted by DWS Investment Management Americas, Inc., Deutsche Asset Management International GmbH or their affiliates that may serve as investment adviser to each Fund. All Covered Officers are also employees of DWS. Thus, in addition to adhering to the Officer Code, these individuals must comply with DWS policies and procedures, such as the DWS Code of Ethics governing personal trading activities, as adopted pursuant to Rule 17j-1 under the Investment Company Act of 1940.^[1] In addition, such individuals also must comply with other applicable Fund policies and procedures.

The DWS Compliance Officer, who shall not be a Covered Officer and who shall serve as such subject to the approval of the Fund’s Board (or committee thereof), is primarily responsible for implementing and enforcing this Code. The DWS Compliance Officer has the authority to interpret this Officer Code and its applicability to particular circumstances. Any questions about the Officer Code should be directed to the DWS Compliance Officer.

The DWS Compliance Officer and his or her contact information can be found in Appendix A.

II.

Purposes of the Officer Code

The purposes of the Officer Code are to deter wrongdoing and to:

promote honest and ethical conduct among Covered Officers, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

promote full, fair, accurate, timely and understandable disclosures in reports and documents that the Funds file with or submit to the SEC (and in other public communications from the Funds) and that are within the Covered Officer’s responsibilities;

promote compliance with applicable laws, rules and regulations;

encourage the prompt internal reporting of violations of the Officer Code to the DWS Compliance Officer; and

establish accountability for adherence to the Officer Code.

Any questions about the Officer Code should be referred to the DWS Compliance Officer.

III.

Responsibilities of Covered Officers

A. Honest and Ethical Conduct

It is the duty of every Covered Officer to encourage and demonstrate honest and ethical conduct, as well as adhere to and require adherence to the Officer Code and any other applicable policies and procedures designed to promote this behavior. Covered Officers must at all times conduct themselves with integrity and distinction, putting first the interests of the Fund(s) they serve. Covered Officers must be honest and candid while maintaining confidentiality of information where required by law, DWS policy or Fund policy.

Covered Officers also must, at all times, act in good faith, responsibly and with due care, competence and diligence, without misrepresenting or being misleading about material facts or allowing their independent judgment to be subordinated. Covered Officers also should maintain skills appropriate and necessary for the performance of their duties for the Fund(s). Covered Officers also must responsibly use and control all Fund assets and resources entrusted to them.

Covered Officers may not retaliate against others for, or otherwise discourage the reporting of, actual or apparent violations of the Officer Code or applicable laws or regulations. Covered Officers should create an environment that encourages the exchange of information, including concerns of the type that this Code is designed to address.

B. Conflicts of Interest

A “conflict of interest” occurs when a Covered Officer’s personal interests interfere with the interests of the Fund for which he or she serves as an officer. Covered Officers may not improperly use their position with a Fund for personal or private gain to themselves, their family, or any other person. Similarly, Covered Officers may not use their personal influence or personal relationships to influence decisions or other Fund business or operational matters where they would benefit personally at the Fund’s expense or to the Fund’s detriment. Covered Officers may not cause the Fund to take action, or refrain from taking action, for their personal benefit at the Fund’s expense or to the Fund’s detriment. Some examples of conflicts of interest follow (this is not an all-inclusive list): being in the position of supervising, reviewing or having any influence on the job evaluation, pay or benefit of any immediate family member who is an employee of a Fund service provider or is otherwise associated with the Fund; or having an ownership interest in, or having any consulting or employment relationship with, any Fund service provider other than DWS or its affiliates.

Certain conflicts of interest covered by this Code arise out of the relationships between Covered Officers and the Fund that already are subject to conflict of interest provisions in the Investment Company Act and the Investment Advisers Act. For example, Covered Officers may not individually engage in certain transactions (such as the purchase or sale of securities or other property) with the Fund because of their status as “affiliated persons” of the Fund. Covered Officers must comply with applicable laws and regulations. Therefore, any violations of existing statutory and regulatory prohibitions on individual behavior could be considered a violation of this Code.

As to conflicts arising from, or as a result of the advisory relationship (or any other relationships) between the Fund and DWS, of which the Covered Officers are also officers or employees, it is recognized by the Board that, subject to DWS’s fiduciary duties to the Fund, the Covered Officers will in the normal course of their duties (whether formally for the Fund or for DWS, or for both) be involved in establishing policies and implementing decisions which will have different effects on DWS and the Fund. The Board recognizes that the participation of the Covered Officers in such activities is inherent in the contract relationship between the Fund and DWS, and is consistent with the expectation of the Board of the performance by the Covered Officers of their duties as officers of the Fund.

Covered Officers should avoid actual conflicts of interest, and appearances of conflicts of interest, between the Covered Officer’s duties to the Fund and his or her personal interests beyond those contemplated or anticipated by applicable regulatory schemes. If a Covered Officer suspects or knows of a conflict or an appearance of one, the Covered Officer must immediately report the matter to the DWS Compliance Officer. If a Covered Officer, in lieu of reporting such a matter to the DWS Compliance Officer, may report the matter directly to the Fund’s Board (or committee thereof), as appropriate (e.g., if the conflict involves the DWS Compliance Officer or the Covered Officer reasonably believes it would be futile to report the matter to the DWS Compliance Officer).

When actual, apparent or suspected conflicts of interest arise in connection with a Covered Officer, DWS personnel aware of the matter should promptly contact the DWS Compliance Officer. There will be no reprisal or retaliation against the person reporting the matter.

Upon receipt of a report of a possible conflict, the DWS Compliance Officer will take steps to determine whether a conflict exists. In so doing, the DWS Compliance Officer may take any actions he or she determines to be appropriate in his or her sole discretion and may use all reasonable resources, including retaining or engaging legal counsel, accounting firms or other consultants, subject to applicable law.^[2] The costs associated with such actions may be borne by the Fund, if appropriate, after consultation with the Fund’s Board (or committee thereof). Otherwise, such costs will be borne by DWS or other appropriate Fund service provider.

After full review of a report of a possible conflict of interest, the DWS Compliance Officer may determine that no conflict or reasonable appearance of a conflict exists. If, however, the DWS Compliance Officer determines that an actual conflict exists, the Compliance Officer will resolve the conflict solely in the interests of the Fund, and will report the conflict and its resolution to the Fund’s Board (or committee thereof). If the DWS Compliance Officer determines that the appearance of a conflict exists, the DWS Compliance Officer will take appropriate steps to remedy such appearance. In lieu of determining whether a conflict exists and/or resolving a conflict, the DWS Compliance Officer instead may refer the matter to the Fund’s Board (or committee thereof), as appropriate. However, the DWS Compliance Officer must refer the matter to the Fund’s Board (or committee thereof) if the DWS Compliance Officer is directly involved in the conflict or under similar appropriate circumstances.

After responding to a report of a possible conflict of interest, the DWS Compliance Officer will discuss the matter with the person reporting it (and with the Covered Officer at issue, if different) for purposes of educating those involved on conflicts of interests (including how to detect and avoid them, if appropriate).

Appropriate resolution of conflicts may restrict the personal activities of the Covered Officer and/or his family, friends or other persons.

Solely because a conflict is disclosed to the DWS Compliance Officer (and/or the Board or Committee thereof) and/or resolved by the DWS Compliance Officer does not mean that the conflict or its resolution constitutes a waiver from the Code’s requirements.

Any questions about conflicts of interests, including whether a particular situation might be a conflict or an appearance of one, should be directed to the DWS Compliance Officer.

C. Use of Personal Fund Shareholder Information

A Covered Officer may not use or disclose personal information about Fund shareholders, except in the performance of his or her duties for the Fund. Each Covered Officer also must abide by the Funds’ and DWS’s privacy policies under SEC Regulation S-P.

D. Public Communications

In connection with his or her responsibilities for or involvement with a Fund’s public communications and disclosure documents (e.g., shareholder reports, registration statements, press releases), each Covered Officer must provide information to Fund service providers (within the DWS organization or otherwise) and to the Fund’s Board (and any committees thereof), independent auditors, government regulators and self-regulatory organizations that is fair, accurate, complete, objective, relevant, timely and understandable.

Further, within the scope of their duties, Covered Officers having direct or supervisory authority over Fund disclosure documents or other public Fund communications will, to the extent appropriate within their area of responsibility, endeavor to ensure full, fair, timely, accurate and understandable disclosure in Fund disclosure documents. Such Covered Officers will oversee, or appoint others to oversee, processes for the timely and accurate creation and review of all public reports and regulatory filings. Within the scope of his or her responsibilities as a Covered Officer, each Covered Officer also will familiarize himself or herself with the disclosure requirements applicable to the Fund, as well as the business and financial operations of the Fund. Each Covered Officer also will adhere to, and will promote adherence to, applicable disclosure controls, processes and procedures, including DWS’s Disclosure Controls and Procedures, which govern the process by which Fund disclosure documents are created and reviewed.

To the extent that Covered Officers participate in the creation of a Fund’s books or records, they must do so in a way that promotes the accuracy, fairness and timeliness of those records.

E. Compliance with Applicable Laws, Rules and Regulations

In connection with his or her duties and within the scope of his or her responsibilities as a Covered Officer, each Covered Officer must comply with governmental laws, rules and regulations, accounting standards, and Fund policies/procedures that apply to his or her role, responsibilities and duties with respect to the Funds (“Applicable Laws”). These requirements do not impose on Covered Officers any additional substantive duties. Additionally, Covered Officers should promote compliance with Applicable Laws.

If a Covered Officer knows of any material violations of Applicable Laws or suspects that such a violation may have occurred, the Covered Officer is expected to promptly report the matter to the DWS Compliance Officer.

IV.

Violation Reporting

A. Overview

Each Covered Officer must promptly report to the DWS Compliance Officer, and promote the reporting of, any known or suspected violations of the Officer Code. Failure to report a violation may be a violation of the Officer Code.

Examples of violations of the Officer Code include, but are not limited to, the following:

Unethical or dishonest behavior

Obvious lack of adherence to policies surrounding review and approval of public communications and regulatory filings

Failure to report violations of the Officer Code

Known or obvious deviations from Applicable Laws

Failure to acknowledge and certify adherence to the Officer Code

The DWS Compliance Officer has the authority to take any and all action he or she considers appropriate in his or her sole discretion to investigate known or suspected Code violations, including consulting with the Fund’s Board, the independent Board members, a Board committee, the Fund’s legal counsel and/or counsel to the independent Board members. The Compliance Officer also has the authority to use all reasonable resources to investigate violations, including retaining or engaging legal counsel, accounting firms or other consultants, subject to applicable law.^[3] The costs associated with such actions may be borne by the Fund, if appropriate, after consultation with the Fund’s Board (or committee thereof). Otherwise, such costs will be borne by DWS.

How to Report

Any known or suspected violations of the Officer Code must be promptly reported to the DWS Compliance Officer.

Process for Violation Reporting to the Fund Board

The DWS Compliance Officer will promptly report any violations of the Code to the Fund’s Board (or committee thereof).

Sanctions for Code Violations

Violations of the Code will be taken seriously. In response to reported or otherwise known violations, DWS and the relevant Fund’s Board may impose sanctions within the scope of their respective authority over the Covered Officer at issue. Sanctions imposed by DWS could include termination of employment. Sanctions imposed by a Fund’s Board could include termination of association with the Fund.

Waivers from the Officer Code

A Covered Officer may request a waiver from the Officer Code by transmitting a written request for a waiver to the DWS Compliance Officer.^[4] The request must include the rationale for the request and must explain how the waiver would be in furtherance of the standards of conduct described in and underlying purposes of the Officer Code. The DWS Compliance Officer will present this information to the Fund’s Board (or committee thereof). The Board (or committee) will determine whether to grant the requested waiver. If the Board (or committee) grants the requested waiver, the DWS Compliance Officer thereafter will monitor the activities subject to the waiver, as appropriate, and will promptly report to the Fund’s Board (or committee thereof) regarding such activities, as appropriate.

The DWS Compliance Officer will coordinate and facilitate any required public disclosures of any waivers granted or any implicit waivers.

VI.

Amendments to the Code

The DWS Compliance Officer will review the Officer Code from time to time for its continued appropriateness and will propose any amendments to the Fund’s Board (or committee thereof) on a timely basis. In addition, the Board (or committee thereof) will review the Officer Code at least annually for its continued appropriateness and may amend the Code as necessary or appropriate.

The DWS Compliance Officer will coordinate and facilitate any required public disclosures of Code amendments.

VII.

Acknowledgement and Certification of Adherence to the Officer Code

Each Covered Officer must sign a statement upon appointment as a Covered Officer and annually thereafter acknowledging that he or she has received and read the Officer Code, as amended or updated, and confirming that he or she has complied with it (see Appendix B: Acknowledgement and Certification of Obligations Under the Officer Code).

Understanding and complying with the Officer Code and truthfully completing the Acknowledgement and Certification Form is each Covered Officer’s obligation.

The DWS Compliance Officer will maintain such Acknowledgements in the Fund’s books and records.

VIII.

Scope of Responsibilities

A Covered Officer’s responsibilities under the Officer Code are limited to:

(1)

Fund matters over which the Officer has direct responsibility or control, matters in which the Officer routinely participates, and matters with which the Officer is otherwise involved (i.e., matters within the scope of the Covered Officer’s responsibilities as a Fund officer); and

(2)

Fund matters of which the Officer has actual knowledge.

IX.

Recordkeeping

The DWS Compliance Officer will create and maintain appropriate records regarding the implementation and operation of the Officer Code, including records relating to conflicts of interest determinations and investigations of possible Code violations.

Confidentiality

All reports and records prepared or maintained pursuant to this Officer Code shall be considered confidential and shall be maintained and protected accordingly. Except as otherwise required by law or this Officer Code, such matters shall not be disclosed to anyone other than the DWS Compliance Officer, the Fund’s Board (or committee thereof), legal counsel, independent auditors, and any consultants engaged by the Compliance Officer.

Appendices

Appendix A:

List of Officers Covered under the Code, by Board:

Fund Board	Principal Executive Officer	Principal Financial Officer	Treasurer
DWS Funds	Hepsen Uzcan	Diane Kenneally	Diane Kenneally
Germany Funds*	Hepsen Uzcan	Diane Kenneally	Diane Kenneally

The Central and Eastern Europe Fund, Inc., The European Equity Fund, Inc. and

The New Germany Fund, Inc.

DWS Compliance Officer:

Eileen Winkler

Head of Employee Compliance Americas

Phone: (212) 250-1544

Email: [email protected]

As of: July 2, 2018

Appendix B: Acknowledgement and Certification

Initial Acknowledgement and Certification

of Obligations Under the Officer Code

Print Name Department Location Telephone

I acknowledge and certify that I am a Covered Officer under the DWS Principal Executive and Financial Officer Code of Ethics (“Officer Code”), and therefore subject to all of its requirements and provisions.

I have received and read the Officer Code and I understand the requirements and provisions set forth in the Officer Code.

I have disclosed any conflicts of interest of which I am aware to the DWS Compliance Officer.

I will act in the best interest of the Funds for which I serve as an officer and have maintained the confidentiality of personal information about Fund shareholders.

I will report any known or suspected violations of the Officer Code in a timely manner to the DWS Compliance Officer.

______________________________ ____________________

Signature Date

Annual Acknowledgement and Certification

of Obligations Under the Officer Code

Print Name Department Location Telephone

I have received and read the Officer Code, and I understand the requirements and provisions set forth in the Officer Code.

I have adhered to the Officer Code.

I have not knowingly been a party to any conflict of interest, nor have I had actual knowledge about actual or apparent conflicts of interest that I did not report to the DWS Compliance Officer in accordance with the Officer Code’s requirements.

I have acted in the best interest of the Funds for which I serve as an officer and have maintained the confidentiality of personal information about Fund shareholders.

With respect to the duties I perform for the Fund as a Fund officer, I believe that effective processes are in place to create and file public reports and documents in accordance with applicable regulations.

With respect to the duties I perform for the Fund as a Fund officer, I have complied to the best of my knowledge with all Applicable Laws (as that term is defined in the Officer Code) and have appropriately monitored those persons under my supervision for compliance with Applicable Laws.

I have reported any known or suspected violations of the Officer Code in a timely manner to the DWS Compliance Officer.

______________________________ ____________________

Signature Date

Appendix C: Definitions

Principal Executive Officer

Individual holding the office of President of the Fund or series of Funds, or a person performing a similar function.

Principal Financial Officer

Individual holding the office of Treasurer of the Fund or series of Funds, or a person performing a similar function.

Registered Investment Management Investment Company

Registered investment companies other than a face-amount certificate company or a unit investment trust.

Waiver

A waiver is an approval of an exemption from a Code requirement.

Implicit Waiver

An implicit waiver is the failure to take action within a reasonable period of time regarding a material departure from a requirement or provision of the Officer Code that has been made known to the DWS Compliance Officer or the Fund’s Board (or committee thereof).

^[1] The obligations imposed by the Officer Code are separate from, and in addition to, any obligations imposed under codes of ethics adopted pursuant to Rule 17j-1 under the Investment Company Act of 1940, and any other code of conduct applicable to Covered Officers in whatever capacity they serve. The Officer Code does not incorporate any of those other codes and, accordingly, violations of those codes will not necessarily be considered violations of the Officer Code and waivers granted under those codes would not necessarily require a waiver to be granted under this Code. Sanctions imposed under those codes may be considered in determining appropriate sanctions for any violation of this Code.

^[2] For example, retaining a Fund’s independent accounting firm may require pre-approval by the Fund’s audit committee.

^[3] For example, retaining a Fund’s independent accounting firm may require pre-approval by the Fund’s audit committee.

^[4] Of course, it is not a waiver of the Officer Code if the Fund’s Board (or committee thereof) determines that a matter is not a deviation from the Officer Code’s requirements or is otherwise not covered by the Code.

President

Form N-CSR Certification under Sarbanes Oxley Act

I, Hepsen Uzcan, certify that:

1)	I have reviewed this report, filed on behalf of DWS Health and Wellness Fund, a series of Deutsche DWS Securities Trust, on Form N-CSR;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4)	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the second fiscal quarter of the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5)	The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

7/30/2018	/s/Hepsen Uzcan
	Hepsen Uzcan
	President

Chief Financial Officer and Treasurer

Form N-CSR Certification under Sarbanes Oxley Act

I, Diane Kenneally, certify that:

1)	I have reviewed this report, filed on behalf of DWS Health and Wellness Fund, a series of Deutsche DWS Securities Trust, on Form N-CSR;

2)	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3)	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, changes in net assets, and cash flows (if the financial statements are required to include a statement of cash flows) of the registrant as of, and for, the periods presented in this report;

4)	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the second fiscal quarter of the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5)	The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting

7/30/2018	/s/Diane Kenneally
	Diane Kenneally
	Chief Financial Officer and Treasurer

President

Section 906 Certification under Sarbanes Oxley Act

I, Hepsen Uzcan, certify that:

1.	I have reviewed this report, filed on behalf of DWS Health and Wellness Fund, a series of Deutsche DWS Securities Trust, on Form N-CSR;

2.	Based on my knowledge and pursuant to 18 U.S.C. § 1350, the periodic report on Form N-CSR (the “Report”) fully complies with the requirements of § 13 (a) or § 15 (d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

7/30/2018	/s/Hepsen Uzcan
	Hepsen Uzcan
	President

Chief Financial Officer and Treasurer

Section 906 Certification under Sarbanes Oxley Act

I, Diane Kenneally, certify that:

1.	I have reviewed this report, filed on behalf of DWS Health and Wellness Fund, a series of Deutsche DWS Securities Trust, on Form N-CSR;

2.	Based on my knowledge and pursuant to 18 U.S.C. § 1350, the periodic report on Form N-CSR (the “Report”) fully complies with the requirements of § 13 (a) or § 15 (d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

7/30/2018	/s/Diane Kenneally
	Diane Kenneally
	Chief Financial Officer and Treasurer

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

Create E-mail Alert Related Categories

SEC Filings

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!

Form N-CSR DEUTSCHE DWS SECURITIES For: May 31

You May Also Be Interested In

Create E-mail Alert Related Categories

Sign up for StreetInsider Free!

Free News Feed